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ABSTRACT 
 
During implantation, uterine stromal cells differentiate into specialized decidual cells, which 
become secretory and support the growth of the embryo before placentation. At the same time, 
new blood vessels begin to form in the maternal decidua from pre-existing vasculature. This 
process termed angiogenesis is critical for the establishment of the placenta and the maintenance 
of pregnancy. Although it is clear that decidualization and angiogenesis play a crucial role during 
early pregnancy, the complex molecular pathways underlying these processes remain largely 
unknown. Our recent studies revealed that RAC1 (Ras-related C3 botulinum toxin substrate 1), a 
pleiotropic signaling factor belonging to the Rho family of GTPases, is induced in the uterine 
stroma during decidualization and angiogenesis, suggesting a role for RAC1 in these critical 
processes. To address the role of RAC1 during pregnancy, we created a conditional knockout of 
the Rac1 gene in the uterus by crossing mice carrying floxed Rac1 with PgrCre mice, thereby 
generating the conditional mutation termed as Rac1d/d. A six-month breeding study indicated a 
severe defect in fertility of the Rac1d/d females. Further analysis revealed that while embryo 
attachment appeared to be unaffected, differentiation and secretory functions of decidual cells were 
impaired in Rac1d/d uteri. This abnormality of decidual cells led to multifactorial consequences, 
including compromised uterine vascular remodeling and angiogenesis, maternal blood vessel 
hemorrhage and placental abnormalities resulting in embryo loss around days 10 to 12 of 
pregnancy. Fetuses that survived to day 15 of pregnancy showed indications of intrauterine growth 
restriction. Based on the results obtained in this dissertation, we propose that RAC1 regulates 
stromal differentiation and secretory functions, which produce and secrete critical local factors 
that regulate vascular remodeling at the maternal-fetal interface and promote proper formation of 
the placental disk. Therefore, RAC1 induced in the uterine stroma during decidualization plays a 
critical role in maintaining proper function of the placental vascular bed and supporting embryo 
growth and development during early and mid-stages of pregnancy.  
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CHAPTER 1: INTRODUCTION 
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Implantation is a fundamental biological process during which the embryo attaches to the uterine 
epithelium, invades the underlying stroma and promotes differentiation of the stromal cells to 
decidual cells, which support embryonic growth and survival. It is a critical step for successful 
establishment of pregnancy [1-11]. In humans, infertility is one of the most common disturbances 
of reproductive health, with 10-15% of couples finding it difficult or impossible to conceive. [4, 
5, 8, 12-16]. Despite significant advances in assisted reproductive technologies (ART), many 
couples experience infertility as a result of failed implantation of the fertilized embryos into the 
uterus and subsequent loss of these embryos. The implantation rates in ART remain low, even with 
high-quality embryos, pointing to the importance of this process as a major cause of pregnancy 
failure and infertility [1-3, 15, 17-21]. Understanding the signaling mechanisms central to embryo 
implantation has the potential to alleviate many problems associated with infertility and improve 
the clinical success of increasingly used ART.  
 
This dissertation focuses on the newly identified role of RAC1 (Ras-related C3 botulinum toxin 
substrate 1), a pleiotropic signaling molecule, in endometrial function during embryo implantation. 
Elucidating the role of RAC1 signaling in the uterus may identify molecular targets for treating 
infertility and improving the outcome of ART. 
 
Implantation is a fundamental biological process during which the embryo comes into intimate 
contact with the uterine epithelium, invades the stroma and establishes the placenta [1-5, 8-10, 22-
28]. This complex multistage process is pivotal for successful establishment of pregnancy. In 
rodents and humans, as the embryo breaches the luminal epithelium following attachment, the 
underlying stromal cells undergo a dramatic transformation to form a specialized tissue, known as 
the decidua [5, 7-9, 22-25]. During this process, known as decidualization, fibroblastic stromal 
cells proliferate and then differentiate into the secretory decidual cells that support embryo growth 
and survival until placentation ensues. The decidual tissue also undergoes extensive remodeling to 
control embryo invasion and accommodate the growing embryo. As the decidua forms around the 
implanted embryo, the uterine endothelial cells proliferate to create an extensive vascular network, 
which is embedded in the decidua and critical for embryo development [23, 29-33]. Even though 
it is clear that decidualization is a key event in establishment of early pregnancy, the signaling 
molecules that participate in the formation and function of this tissue remain poorly understood.  
3 
To gain an insight into the signaling pathways that are involved in the decidualization process, we 
performed gene expression profiling of RNA collected from mouse uteri before and after decidual 
stimulation. Our studies revealed that the gene encoding the Rac1, a pleiotropic signaling 
molecule, is induced in uterine stroma at the time of decidualization. RAC1 is a member of the 
Rho family of GTPases that regulate a wide range of cellular processes, including cell 
proliferation, differentiation, cell-cell adhesion, endothelial cell function, and cell motility via actin 
cytoskeleton remodeling. Because decidualization encompasses many of these physiological 
events, it is possible that RAC1 regulates some of these processes during early pregnancy. In 
support of this notion, a recent study has shown that invasion of the human embryo into 
endometrial stroma in vitro involves motility of human endometrial stromal cells and that this 
motility is dependent on the activity of the Rho GTPase RAC1 [7, 26]. 
 
To address the role of RAC1 in vivo during decidualization, we employed a loss-of-function 
approach using genetically engineered mice. In this project, we generated a mutant mouse model 
in which Rac1 gene is ablated from uterine stroma, characterized the mouse model and identified 
the pathways that mediate RAC1 function in the uterus during decidualization. An in depth 
analysis of this new mouse model is predicted to improve our understanding of the cause and 
consequence of pregnancy complications involving impaired implantation, dysregulated 
decidualization and placental complications in the human.   
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CHAPTER 2: REVIEW OF RELEVANT LITERATURE 
 
 
  
5 
2.1 Defining the problem: Clinical evidence for recurrent miscarriage and pregnancy loss 
 
In recent years, worldwide, there has been a marked increase in human infertility, as well as the 
use of assisted reproductive technologies (ART) [34-37]. The increased use of ART and the trend 
towards low fertility has been attributed to the socioeconomic status, career demands in women, 
improvement in contraception, or education, however biological factors that might contribute to 
this decline need consideration [34]. In fact, clinically it is recognized that miscarriage and early 
implantation failure are amongst the most common complications in pregnancy [6, 7, 26, 38, 39]. 
In many cases, this goes unnoticed because most miscarriages occur within the first 10 to 20 weeks 
of gestation. Although pre-implantation pregnancy loss is considered to be normal in mammals as 
an evolutionary advantage to select the best possible embryos, dysregulation of any of the events 
before, during, or after implantation will lead to termination of pregnancy [1]. This concept has 
created a challenge to researchers and clinicians who are trying to uncover ways to circumvent 
human infertility, and at the same time, selecting for healthy offspring.  
 
Recurrent miscarriage, which is defined clinically as pregnancy loss in more than three 
reproductive cycles, is becoming more frequent in our society and in many cases (approximately 
50%) the reasons leading to pregnancy loss remains unknown [40, 41]. The available data of a 
large prospective register linkage study have shown that maternal age at conception is a strong risk 
factor for miscarriage [42], and the risk of fetal loss increases steeply after the age of 35 years, 
rising from 9% at 20–24 years to nearly 75% at 45 years and older [42-44]. Certainly there is an 
urgent need to gain an understanding of the genetic- and molecular-basis of miscarriage, with 
particular emphasis on the maternal environment that leads to pregnancy failure. A literature 
review was undertaken to obtain current knowledge about certain maternal factors that may 
contribute to miscarriage, as well as the influence of the uterine environment, and current 
treatments for recurrent miscarriage.  
 
2.1.1 Factors that may contribute to miscarriage  
 
Recurrent miscarriage is clinically defined, by many clinicians, as the loss of three or more 
consecutive pregnancies, and depending on how conservative the clinicians are when diagnosing 
6 
a patient with recurrent miscarriage, the incidence can affect anywhere from 1 to 5 % of couples 
trying to conceive. It has been attributed to either genetic, structural, infections, endocrine, 
immune, or unexplained causes [40, 44, 45], and in many cases, miscarriage is also associated with 
psychological morbidity and stress for the patients. Very often women, more than men, attending 
fertility clinics are clinically depressed, and about 20% of these women have anxiety levels that 
are similar to those in psychiatric outpatient populations [17-20, 46, 47].  
 
2.1.1.1 Congenital abnormalities 
 
Although several known factors put some women at risk for miscarriage including malformation 
of the uterus, diabetes, obesity, and alcohol use, the relationships between these conditions and 
recurrent miscarriage have not been extensively studied and remain uncertain. Congenital uterine 
abnormalities are commonly reported in women with recurrent miscarriage [48-51]. However, 
some have argued that congenital uterine abnormalities might not represent a barrier anymore, 
because there are women with structural abnormalities that have conceived children without 
complications. The fact is that early miscarriages, especially the sporadic ones, are typically 
associated with chromosome abnormalities of the embryo, which result in implantation failure or 
growth arrest of the embryos leading to termination of pregnancy. Miscarriages without fetal 
chromosomal abnormality or malformation are often thought to be a result of abnormal trophoblast 
invasion and development [45, 52-54]. There is also evidence to suggest that impaired trophoblast 
growth and invasion may be caused by an increased local or systemic immunological reaction to 
the fetus or trophoblast [6]. In contrast to sporadic miscarriage, recurrent miscarriage tends to 
occur even when the fetus has a normal chromosome complement, suggesting that the uterine 
environment plays a role in determining pregnancy outcome. Therefore, recurrent miscarriage 
undoubtedly is as complex disease, which may or may not have an underlying genetic component.  
 
2.1.1.2 Vascular problems and bleeding disorders 
 
It is well established that proper vascularization of decidua is critical for the success of pregnancy, 
and it has been suggested that vascular disorders may play a role in pregnancies with complications 
[55-58]. More recently, however, hypercoagulation disorders have been implicated in recurrent 
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pregnancy loss, which widens the scope of investigations and potential management to treat 
recurrent miscarriage. However, data on the frequency of genetic thrombophilia are limited by the 
small number of individual studies [44].  
 
In some cases of early pregnancy failure, miscarriage has been attributed to the onset of a 
precocious maternal blood flow leading to increased oxidative stress [52, 59]; and this is 
independent of the karyotype of the conceptus [60]. Moreover, the early onset of maternal 
circulation, which results in increased oxygen levels, can lead to widespread trophoblast damage 
and placental degeneration [52, 59]. Furthermore, oxidative stress may modulate the architecture 
of vasculature and the expression of angiogenic factors resulting in a dysregulated vascularization 
[61]. Consistent with this observation, it has been reported that in women with miscarriages, there 
is a reduced expression of vascular endothelial growth factor (VEGF) and its receptors [62]. 
Similarly, the decidual tissues of women with recurrent miscarriages show imbalance of the 
expression ratio of angiopoietins (Angpt2/Angpt1), in favoring Angpt1, compared with the 
predominance of Angpt2 in normal pregnancies [63]. While angiopoietin 2 is maximally expressed 
during the early stages of pregnancy (i.e. first trimester) and declines afterwards, Angpt1 
expression increases towards the third trimester, suggesting blood vessel stability [64]. Overall, 
the data suggest that the role ANGPT2 during the first trimester is in branching angiogenesis, 
leading to elongating and sprouting vessels and complex vascular network, whereas ANGPT1 
predominates in the third trimester enhancing non-branching angiogenesis, maturation and 
stabilization of the vascular network [58, 63, 64]. Therefore, a strong association between vessel 
density and miscarriages is not farfetched. 
 
2.1.2 Intrauterine growth restriction 
 
Intrauterine growth restriction (IUGR) occurs with an incidence of 4 to 7% of all births, resulting 
in low birth weight and preterm delivery. IUGR is associated with increased neonatal morbidity 
and mortality because of placental problems leading to nutritional deficiencies [65, 66]. Several 
risk factors have been associated with the pathogenesis of IUGR, which include chromosomal 
abnormalities, infectious diseases, and defective vascularization of the uteroplacental unit. 
Consistent with the latter, placental samples from women with IUGR showed a significantly lower 
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number of capillaries and a decreased capillary area in terminal villi of the placenta compared to 
those with normal term pregnancies [67, 68]. Interestingly, previous studies have shown that in 
pregnancies with IUGR, there is an apparent reduction in cytotrophoblast proliferation, poor 
placental blood vessel development and an apparent increase in placental oxygen [52, 69, 70] [60]. 
Given that hypoxia promotes VEGF production, and thus angiogenesis, it has been suggested that 
the relatively high oxygen levels in placentas with IUGR, will limit angiogenesis [69]. Consistent 
with this notion, Khaliq et al. [71] reported a decreased expression of VEGF and an altered 
expression of angiopoietins in IUGR placentas. The opposite is observed during the first trimester 
of pregnancy where hypoxia upregulates VEGF secretion in the placenta. Given that trophoblasts 
express the receptors for both VEGF and angiopoietins, which are known to influence behavior in 
these cells, it is possible that a dysregulation of angiogenic factors can lead to perturbations in 
proliferation and invasion of the trophoblast cells, as well as abnormal trophoblast migration and 
differentiation (leading to placental abnormalities). Collectively, these result in an insufficient 
exchange of oxygen and nutrients [72] in an otherwise normal embryo. 
 
During the development of the placenta, trophoblast cells invade into the uterine tissues to gain 
access to the maternal blood supply [73]. This process requires a balanced interplay between the 
factors that promote and restrain trophoblast invasion. Consistent with this notion, early work has 
suggested that the uterine microenvironment controls invasion of trophoblast, supporting the role 
of the maternal decidual tissue as a restrain to trophoblast invasion [57, 74]. These studies also 
imply that factors that promote trophoblast invasion are produced and secreted by the trophoblast 
cells. Supportive of this model, it has been shown that the embryo secrete insulin-like growth 
factor (IGF) 2, which drives trophoblast migration [1, 5, 9, 10, 29, 32, 75-77], as well as matrix 
metalloproteinases (MMPs), which degrade the decidual extracellular matrix (ECM) [5, 78, 79]. 
To counteract these factors, the maternal decidua secretes tissue inhibitors of MMPs (TIMPs) [80, 
81], as well as several IGF-binding proteins (IGFBP), including IGFBP1 [82-85] and IGFBP4 [65, 
86-92]; molecules that are known to inhibit trophoblast invasion. Similarly, an interplay between 
IGF and IGFBP exists, where IGF2 inhibits maternal decidual IGFBP1 and TIMP-3 expression, 
supporting paracrine actions of trophoblast-derived IGF2 on decidual regulators of invasion [93]. 
Indeed, mounting evidence suggests that IGF and IGFBPs play critical roles during early 
pregnancy, and it has been suggested that alterations of the IGF/IGFBP system can have serious 
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complications leading to IUGR [84, 85, 94]. In concordance with the importance of the IGF/IGFBP 
system, overexpression of IGF1 [95] or IGFBP1 [94] in animal models leads to fetal loss or altered 
placental development, respectively. In the clinics, women that are destined to deliver a growth-
restricted infant, display elevated levels of serum IGFBP4 compared to women with normal 
pregnancies [65]. It is clear that the IGF family of proteins play an important role during pregnancy 
overlapping the window of implantation and placentation [82, 85, 86, 90, 93, 96, 97]. Although 
there are species differences, studies on transgenic mice have provided insights into the 
IGF/IGFBP system during pregnancy [94, 95, 98-101].  
 
2.1.3 Assisted reproductive technologies 
 
The use of assisted reproductive technologies (ART) has increased dramatically in the last decade 
[37, 39]. Many couples that have problems conceiving turn to ART to aide in this process. To 
increase the likelihood of successful pregnancy, pre-implantation genetic screening of biopsied 
blastomeres during in vitro fertilization has been recommended in order to prevent the transfer of 
karyotypically abnormal embryos in couples with normal karyotypes. However, this practice may 
not be effective in couples with recurrent idiopathic miscarriage due to limitations of genetic 
testing [102]. Nonetheless, there is a need for research to investigate potential factors that could 
predispose an individual to recurrent pregnancy loss.  
 
2.2 Uterine receptivity, the window of implantation, and early pregnancy in the mouse 
 
Steroid hormones, 17β-estradiol (E2) and progesterone (P4), regulate cell proliferation, 
differentiation, and vascular remodeling of the endometrium by binding to their respective nuclear 
receptors estrogen, ESR1/ERα (estrogen receptor α) and PGR (progesterone receptor). In each 
reproductive cycle, under the influence of these hormones, the endometrium becomes competent 
to receive an embryo during a short duration of time known as “window of receptivity” [11, 103-
106] (Figure 2.1). Intimate interactions between the uterus and fetus occur during this period that 
promotes implantation leading to establishment of pregnancy [11, 107, 108]. About one third of 
human pregnancies end in spontaneous abortion. Indeed, implantation failure still remains an 
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unsolved problem in reproductive medicine. It is a major cause of infertility [6, 37, 39, 45] and 
represents a major challenge in ART.  
 
2.2.1 Critical events during pregnancy 
 
The concomitant actions of steroid hormones prepare the endometrium for the arrival of an embryo 
and allow it to invade so that pregnancy is established. Whereas E2 initially regulates uterine 
growth by stimulating epithelial cell proliferation and edema, P4 is mostly required for the 
differentiation of stromal cells during pregnancy. Indeed genomic profiling of mouse and human 
endometrium has uncovered a complex, yet highly conserved network of steroid-regulated genes 
that supports stromal cell differentiation. In order to advance our understanding of the mechanisms 
regulating critical aspects of pregnancy and better address the clinical challenges of infertility, it 
is important to integrate the information gained from the human and mouse models [2, 109, 110]. 
Undeniably functional studies using transgenic mouse models over the past several years have 
yielded valuable information regarding the molecular basis of pregnancy complications in humans 
[25, 111]. Below we summarize some of the critical events required for the successful 
establishment of pregnancy. 
 
2.2.1.1 Implantation  
 
Embryo implantation and placentation are critical events that support embryonic growth and 
ultimately delivery of a live offspring in the mammalian system. [1, 25]. Failure of the 
endometrium to provide a permissive growth environment can severely compromise the outcome 
of pregnancy, leading to an impaired embryonic development or death. Despite some species 
differences, in general, the principles of implantation and placentation are well conserved among 
mammalian species [1, 5, 10, 14, 27, 28, 112, 113]. In species with invasive placentation, 
implantation into the uterine endometrium is an absolute requirement and involves a series of 
complex interactions between the implanting embryo and the endometrium [5, 41, 114-116]. 
 
In mice following fertilization, which typically occurs on the day the copulatory plug is found, is 
termed as day 1 of pregnancy (Figure 2.2). The newly formed embryo then travels through the 
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oviduct and enters the uterine cavity on day 4 of pregnancy [41, 107, 117]. The embryo will then 
begin an intimate crosstalk with the endometrium to initiate the implantation process (Figures 1.2 
and 1.3) [1, 5, 116]. A transitory rise in E2, which in mice occurs on noon of day 4 pregnancy, 
known as “nidatory estrogen”, is responsible for the initiation of implantation [1, 5, 8, 14, 118]. 
The necessity of the pre-implantation estrogen was established in the delayed implantation mouse 
model, where ovariectomy before the nidatory estrogen surge prevents implantation. Replacement 
of estrogen in these ovariectomized mice rescues implantation [103, 106]. Although is clear that 
steroid hormones regulate embryo implantation in humans, it is still debatable whether a similar 
E2 surge initiates embryo implantation in these species [14]. 
 
In a series of coordinated steps, i.e. apposition, adhesion, and invasion, the cells of the 
trophectoderm penetrate into the stromal compartment of the endometrium and invasion into the 
antimesometrial side of the uterus, i.e. the uterine side opposite to the mesometrial ligament starts 
pregnancy [41, 117]. During this period, the uterus under the influence of P4 and the E2 becomes 
receptive, a critical step for the initiation of this process (Figures 1.1 and 1.2). However, the uterus 
will not remain permanently in a receptive phase and between 24 to 36 hours after the nidatory E2, 
the uterus becomes refractory to implantation [11, 104, 105].  
 
2.2.1.2 Decidualization: A key event for successful establishment of pregnancy 
 
Maternal-fetal dialogue involving an intimate interaction between the specialized trophectodermal 
cells of the embryo and the receptive uterine lining of the mother starts pregnancy [5, 10, 25]. The 
attachment and breaching of the implanting embryo through epithelial barrier causes the 
underlying fibroblastic stromal cells to undergo further proliferation and subsequent differentiation 
into polyploid secretory decidual cells (Figure 2.3), in a process termed as decidualization [10, 
108, 116, 119]. During decidualization, stromal cells transform into epitheloid cells that have 
unique biosynthetic and secretory properties [23-25, 29, 33, 80, 84, 90, 91, 120-123]. These cells 
are responsible for producing and secreting hormones, growth factors, and cytokines, which are 
essential for tissue and vascular remodeling to support the growth and development of the embryo 
until the establishment of the chorioallantoic (definitive) placenta. This typically happens on day 
9 of pregnancy in rodents [1, 5, 9, 10, 23, 28, 29, 31, 78, 112, 124-133]. Another important feature 
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of the decidua is to resist the invasive capacity of trophoblasts by secreting products (such as 
IGFBPs, TIMPs) that bind to trophoblast and modulate their migration and invasion [5, 80, 81, 83, 
84, 86, 87, 122, 123, 134]. The invading trophoblasts secrete MMPs that degrade the decidual 
ECM [5, 23, 78] and the decidual cells express high levels of TIMPs [135, 136], which control 
trophoblast invasion. The maternal decidua allows trophoblast invasion far enough to access the 
maternal blood supply, but not too far that the mother becomes endangered [23, 25, 29, 94, 130, 
137, 138]. As embryo invades, it initiates a connection with the maternal vasculature and 
ultimately, placentation ensues. Clearly, the formation of a functional placenta requires extensive, 
but tightly regulated, invasion of the trophoblast through the endometrium [23, 25, 29, 94, 137, 
138]. Insufficient trophoblast invasion can lead to number of placental complications such as 
preeclampsia [139-143], whereas excessive invasion is associated with disorders such as placenta 
accreta [125, 144-148].  
 
The decidual cells are also thought to provide an immune barrier to the mother from the allogenic 
embryo [23, 29, 149-151]. Mature decidual cells produce and secrete cytokines and chemokines 
that maintain the trophoblast in its allogenic phenotype to avoid being targeted by the maternal 
immune system. To this end, it has been thought that the modulation of the maternal immune 
system is mediated by the recruitment of peripheral and resident leukocytes in the maternal 
decidua, which provide local immunomodulation and support placental development [131, 143, 
152, 153]. Indeed an immune environment is established in the endometrium, which is permissive 
to the developing embryo [5, 130, 143, 152, 153]. 
 
The initiation of the stromal differentiation process can be monitored by the gene expression or 
enzymatic activity of liver/kidney/bone alkaline phosphatase (ALPL, Figure 2.4) [154]. Around 
day 4 midnight of pregnancy (or early day 5 morning), after the embryo has embedded itself into 
endometrium, it is surrounded by the newly formed decidual cells of the primary decidual zone 
[29, 155]. By day 6 and 7 of pregnancy, the stromal cells next to the primary decidual zone begin 
to proliferate and then differentiate to form the secondary decidual zone (Figure 2.3B), forming 
the decidua capsularis [1, 155]. As these cells differentiate, the cells of the antimesometrial 
decidua, which differentiate first, will exit the cell cycle and begin expressing decidual prolactin-
related protein (PRL8A2/dPRP), which is typically used to assess the differentiation potential of 
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these cells [22, 156-158]. By day 8 of pregnancy, the differentiation program continues in the 
mesometrial side of the uterus, i.e. the side that is closest to the principal maternal blood vessels, 
and later forms the decidual basalis. These two decidual cell populations differ not only in their 
morphology, but also by the genes they express and the putative roles they play in pregnancy [150]. 
The antimesometrial decidua is formed primarily by giant, polyploid, and closely packed decidual 
cells, whereas the mesometrial decidua is formed by much smaller, loosely packed decidual cells. 
It is relatively easy to separate these two sub-populations by the differences in their size and density 
[150, 155]. Also, it is assumed that the mesometrial decidual cells regulate many important aspects 
of vascular remodeling (Figure 2.3) [23, 29-32], energy storage and metabolism [159-161], as well 
as placentation (Figure 2.5) [28, 31, 112]. By day 10 of pregnancy, however, the terminally 
differentiated stromal cells undergo apoptosis to accommodate the growing embryo and 
placentation ensues to maintain the conceptus until term [23, 150, 155]. Therefore, perturbations 
in the decidual program will lead to pregnancy complications that may manifest in early pregnancy 
loss. In humans, however, it should be noted that the stromal cell differentiation program is 
initiated in the absence of embryo, but the extent of decidualization as well as vascular remodeling 
increases significantly with the onset of implantation and establishment of pregnancy [33]. 
 
Experimentally, stromal cell differentiation into decidual cells can be studied independently of the 
implanting embryo in an in vivo [154, 162, 163] as well as an in vitro model systems [164, 165]. 
In vivo, the experimentally-induced stromal differentiation is performed by ovariectomizing non-
pregnant mice, then replacing estrogen and progesterone, in a timely manner. Once the uterus is 
primed, an external stimulus (most often oil injection) is given to one uterine horn, whereas the 
other horn remains unstimulated, and serves as an internal control [163]. The in vivo 
experimentally-induced differentiation model has been used extensively, by our laboratory, as well 
as others, to establish the importance of steroid hormones in the regulation of stromal 
differentiation during decidualization.  
 
2.2.1.3 Angiogenesis and vascular remodeling are essential for maintenance of pregnancy 
 
The establishment of an extensive angiogenic network during decidual transformation [23, 31, 57, 
116, 166-168] is a key physiological event that supports early pregnancy and embryo development 
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(Figure 2.3). In mice, the initiation of vascular remodeling occurs soon after implantation and 
manifests as an increase in microvascular permeability; only seen at the sites of embryo apposition 
[116, 169-171]. Chicago blue dye injected via tail vein can be used to determine the sites of embryo 
attachment on day 5 and 6 of pregnancy [169, 171]. This increase in vascular permeability is 
thought to be a pre-requisite for embryo implantation [169, 172]. Under the influence of estrogen, 
vascular-endothelial growth factor (VEGF) is produced and secreted as early as day 5 of pregnancy 
[173-175]. This potent mitogen stimulates endothelial cells to proliferate and is thought to play a 
major role in uterine angiogenesis during the decidualization process [176-178]. Because Vegf is 
induced and maintained during the stromal cell differentiation process, it is considered as a marker 
of decidualization [178, 179]. VEGF is a potent driver of angiogenesis, however, other cytokines 
and growth factors are also recognized as angiogenic promoters. Therefore, one or more factor(s) 
may be acting in concert with VEGF to mediate endometrial angiogenesis. 
 
Vascular endothelial growth factor is a key regulator of angiogenesis [180, 181], and targeted 
deletion of gene encoding Vegf results in embryonic death due to abnormal blood vessel formation 
[181, 182]. VEGF has been shown to be one of the earliest genes activated during pre-implantation 
embryo development [183]. Extensive analyses on the expression of VEGF, its steroid hormone 
regulation, and involvement of specific receptors during pregnancy have suggested a critical role 
for the VEGF system in pregnant uterus [175, 183]. VEGF is a heparin binding homodimeric 
glycoprotein that mediates its action through tyrosine kinase receptors, namely VEGFR1/FLT1, 
VEGFR2/FLK1, as well as the glycoprotein co-receptor neuropilin 1 (NRP1) [168, 178, 184, 185]. 
VEGFR2/FLK1 is the predominant VEGF receptor in the uterus [185], and binding of VEGF to 
this receptor activates the VEGF signaling cascade. VEGFR1/FLT1 is also expressed in the uterus, 
but is thought to have minimal to no effect during uterine angiogenesis [185]. Previous studies 
have also shown that the human blastocysts are able to stimulate angiogenesis via the production 
of significant amounts of VEGF [186]. Several studies have reported the expression of VEGF and 
its receptors, in first-trimester human decidua basalis and parietalis, as well as in several cell types, 
including endothelial cells, epithelial cells, macrophages and trophoblasts [187, 188]. VEGFA 
(also indicated as VEGF), the predominant vascular endothelial growth factor that drives blood 
vascular angiogenesis, has also been shown to stimulate trophoblast proliferation and invasion 
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[189]. Therefore, VEGFA may play an active role in trophoblast invasion and angiogenesis [187, 
188]. 
 
Although it is clear that estrogen and progesterone play a major role during endometrial 
angiogenesis [175, 178, 190], their specific roles in this process remain unsolved and controversial. 
Whereas vascular permeability is under the regulation of estrogen [191], endothelial cells seem to 
proliferate in response to progesterone [192, 193]. The importance of estrogen during angiogenesis 
was recently studied in our laboratory [32, 194]. Laws et al. [32] clearly showed that ablation of 
connexin 43 (Gjp1/Cx43), an estrogen-regulated gene from the decidual cells, caused a defect in 
stromal cell differentiation and impaired vascular remodeling, primarily due to a marked reduction 
in hypoxia inducible factors (Hif1α and Hif2α), Vegfa, angiopoietins (Angpt2 and Angpt4). 
Similarly, Das et al. [194] reported that inhibition of local uterine estrogen can effectively impair 
the production of pro-angiogenic factors, such as angiopoietins, which are well-known regulators 
of angiogenesis [113].  
 
During pregnancy, members of the angiopoietin family including Angpt1 and Angpt2, along with 
Tek/Tie2, are expressed in the endometrium during stromal cell differentiation and modulate 
angiogenesis [195, 196]. Angiopoietins are a class of angiogenic regulators that complement 
VEGF signaling [180, 184, 197]. Angiopoietins mediate their actions by binding to the tyrosine 
kinase receptor TEK/TIE2, and in the presence of VEGF, angiopoietins, especially ANGPT2, 
promotes vascular remodeling in front of the invading vascular sprouts [184, 197, 198]. Although 
it has been reported that steroids regulate the expression of these genes in the endometrium [192, 
193], the exact mechanism and signaling pathways by which these hormones regulate angiogenesis 
remain unclear. 
 
Hypoxia is a detectable feature in the uterine environment during embryonic development [199-
201]. HIFs are major transcriptional regulators of Vegf. They play a critical role in maintaining the 
physiological balance of oxygen tension and are closely associated with angiogenesis [1, 199, 202-
205]. Oxygen homeostasis is critical for cell survival and in response to hypoxic conditions, cells 
activate the transcription of Hif1α to restore homeostasis [1, 206, 207]. Activation of HIF 
stimulates Vegf expression, which promotes angiogenesis, thereby restoring oxygen homeostasis. 
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Both Hif1α and Hif2α transcripts are upregulated during the early stages of implantation and their 
expressions are maintained during decidualization [1, 199, 202-204]. It has been reported that 
EPAS1/HIF2α complements the action of HIF1α to regulate VEGF expression [205, 208]. 
Previous studies from our laboratory have demonstrated that both Angpts and Hif2α are regulated 
by local endometrial E2 production during decidualization, thus contributing to VEGF regulation 
and angiogenesis [194]. 
 
Whereas many of the early events leading to angiogenesis and vascular remodeling are regulated 
by estrogen during pregnancy, progesterone also plays a major role in these events. Several in vivo 
studies have suggested a pro-angiogenic role for progesterone [192, 193]. Human endometrial 
endothelial cell cultures show an enhanced capacity to form tube-like structures and sprouts when 
progesterone is added to the culture media [209]. It has been suggested that P4-induced 
proliferation is most likely caused by a direct, but non-genomic effect of progesterone. Consistent 
with this notion, Ma et al. [192] reported progesterone-mediated induction of endothelial cell 
proliferation in ovariectomized mice and suggested the involvement of VEGF and its receptor 
VEGFR2/FLK1 in conjunction with NRP1 in this process. Furthermore, progesterone-induced 
endometrial endothelial cell proliferation is thought to be mediated by multiple angiogenic 
mechanisms [32, 194, 210-212] and regulatory factors, acting in a paracrine manner between cells 
within the endometrium [210-212]. These paracrine effects are absent in vitro, which could explain 
the disparity between some in vitro and in vivo observations. 
 
With the progression of decidualization and pregnancy, new blood vessels begin to form a vascular 
plexus in the mesometrial side of the uterus (Figure 2.3) [23, 31, 57, 166, 167]. Moreover, the 
specific pattern this plexus acquires is thought to be influenced by signals that originate from the 
embryo [30, 130, 198]. In the experimentally-induced differentiation model the specific pattern of 
vascular remodeling that is typically observed in pregnancy, is not acquired [30, 198]. It is believed 
that the concerted actions of steroids, in addition to the signals originating from the embryo, are 
thought to regulate the final outcome of uterine angiogenesis during pregnancy [23, 29, 30, 32, 57, 
112, 130, 176, 194, 213]. 
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2.2.1.4 Placentation  
 
Whereas placentation is highly variable and species-dependent, the primary and major goals of the 
placenta are to 1) anchor the conceptus in the maternal uterine wall, 2) establish a vascular supply 
that enable optimal growth and development of the conceptus, 3) and protect the fetal allograft 
from rejection [5, 9, 23, 28, 29, 31, 112, 124-128, 149-151, 214]. To achieve these goals, there are 
complex molecular dialogues that take place between the maternal decidua and the developing 
conceptus, as well as the placental structures [1, 5, 10, 23, 29, 78, 112, 127-133, 215].  
 
During the early stages of gestation, it is thought that the developing embryo is supported by the 
secretions of the luminal epithelium of the oviductal cells and those from the uterus [116, 216]. 
However, as the embryo grows in size and the trophectoderm begins to differentiate, the nutritional 
requirements of the embryo change. Initially, the primary sources of energy for the early embryo 
are pyruvate, lactate, and amino acids. But after compaction of the morula, glucose becomes the 
primary source of energy for the embryo [28, 116, 217, 218]. At this point, the developing embryo 
involving a dynamic crosstalk between trophoblasts and the maternal decidua begins attachment 
and invasion through the luminal epithelium into the maternal endometrium [1, 5, 10, 29, 171, 
219].  
 
2.2.1.4.1 Placentation in humans and mice 
 
Mice and humans exhibit hemochorial-type of placenta, and although there are some differences 
in the architectural details of these placentas, their overall structures and the molecular 
mechanisms underlying placental development are thought to be quite similar [28, 126-128, 132, 
220]. As a consequence, the rodent system, especially the mouse, has been extensively used as a 
model for studying the fundamentals of placental development. In mice, placental development 
begins on day 4 of pregnancy when the blastocyst is formed (Figure 2.5) [5, 28, 126, 128]. Around 
the time of invasion into the endometrium on day 5 of pregnancy, the mural trophectoderm cells, 
i.e. those not in contact with the inner cell mass, proliferate and begin to give rise to two diploid 
cell types: the extraembryonic ectoderm – presumably those which give rise to the chorionic 
trophoblast forming the placental labyrinth and are analogous to cytotrophoblast of the human 
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placenta – and ectoplacental cone – presumably those which give rise to the spongiotrophoblast, 
and are thought to support the developing labyrinth [28, 126, 128, 132]. The trophoblast cells that 
are farthest from the inner cell mass stop dividing, but continue endoreduplication of the genome 
without mitosis, and become the trophoblast giant cells (analogous to human extravillous 
cytotrophoblast cells). The trophoblast giant cells form the interface with maternal decidua and are 
capable of invasion into the endometrium [28, 31, 124, 132]. The cells from the ectoplacental cone 
and extraembryonic ectoderm lineages thus establish the three layers of murine placenta: 1) The 
labyrinth zone, which is the zone closest to the chorionic plate; 2) the juctional zone, which 
supports and surrounds the labyrinth and is composed spongiotrophoblasts and trophoblast 
glycogen cells; and the final layer 3) the trophoblast giant cells, which are at the maternal-fetal 
interphase and a subgroup of these cells invade the maternal blood vessels [5, 10, 28, 31, 126, 127, 
132, 214]. Although it is clear that there are interactions and crosstalk between the maternal and 
embryonic cells, however, due to the complex nature of these interactions, the mechanism 
underlying the placental formation is not clear.  
 
2.2.1.4.2 Regulation of trophoblast invasion and placental pathologies 
 
An important function of the decidua is to resist the invasive capacity of trophoblasts by secreting 
factors that bind to trophoblasts and modulate their migration and invasion [23-25, 29, 33, 80, 84, 
90, 91, 120-123, 127, 221]. Beyond the in vitro data, which strongly support the concept of a 
“decidual barrier”, the results from classical embryo transfer experiments support the role of the 
decidua in regulating trophoblast invasion. When mouse blastocysts are transferred to subepithelial 
ectopic sites (such as kidney, testis, or anterior chamber of the eye), the embryo is able to penetrate 
into the non-decidualized connective tissue much more deeply than into uterine decidua [222-225]. 
Similar examples of this phenomenon have been reported in human pregnancies established at 
ectopic pregnancy sites. In oviductal pregnancies, for example, the trophoblast cells tend to be 
more invasive [226]. It has been speculated that a potential reason for this excessive invasion is 
because the pseudo-decidualized oviductal cells [129, 227] do not produce IGFBP1 [129]. 
Furthermore, it has been reported that excessive trophoblast invasion or ectopic pregnancy tends 
to occur in tissues that exhibit impaired decidualization [129, 227]. Thus the unique feature of the 
decidua to suppress uncontrolled trophoblast invasion, provides a possible explanation for why, in 
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pathological conditions where the embryo invades ectopic sites, trophoblast invasion tends to be 
more invasive [127, 129, 226]. In more severe cases, where the decidual barrier is defective, little 
or too much invasion can result in further complication to the mother. [39, 53, 54, 58-60]. One of 
the hallmarks of preeclampsia is shallow trophoblast invasion, thought to cause an inadequate 
spiral artery remodeling, leading to placental hypoxia. It is widely accepted that placental hypoxia 
initiates the cascade of events that ultimately results in the maternal manifestations of high blood 
pressure and proteinuria [61-64]. Similarly, in placenta accreta it has been proposed that either 
primary deficiency of decidua or abnormal maternal vascular remodeling leads to excessive 
trophoblastic invasion, resulting in massive postpartum hemorrhage and commonly leads to 
emergency hysterectomy [65-70]. Nonetheless, the formation of the placenta is a critical process 
during embryogenesis, and without a healthy placenta, the embryo will not survive and this 
malformation can trigger a spontaneous abortion.  
 
2.2.1.4.3 The mid-stages of placentation in the mouse 
 
Day 10 of pregnancy is a critical stage in mouse placenta. At this point, the chorioallantoic 
circulation becomes the primary support for the growing embryo. The placenta forms an essential 
interface between the maternal and fetal layers that allow the exchange of oxygen, nutrients, and 
waste products to provide a nourishing environment to the growing fetus [5, 9, 28, 31, 112, 176]. 
By day 12 of pregnancy, the fetal trophoblast cells start to invade into the maternal decidua to 
reach spiral arteries and induce modifications with make high capacitance, low resistant blood 
vessels [167, 228-232]. As a consequence of trophoblast invasion, the endometrial spiral arteries 
undergo dilation, which results from the loss of smooth muscle cells surrounding the arterioles 
[233]. Therefore, defective or improper invasion of fetal trophoblast cells into maternal decidua 
can result in various clinical problems such as, spontaneous abortion, preeclampsia, and/or 
intrauterine growth restriction [173, 174, 234-237].  
 
2.3 Rho GTPases 
 
The Ras Homology (Rho) family of guanosine triphosphatases (GTPases) are small signaling G 
proteins (~21 kDa), and belong to the subfamily of the Ras superfamily of proteins (Figure 2.6). 
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Members of the Rho GTPase family regulate many aspects of actin dynamics and are found in 
organisms raging from plants and Caenorhabditis elegans, to mice and humans. While their first 
discovered role was regulation of actin dynamics in fibroblast cells [238], recent evidence has 
suggested that the members of this family play important roles in signal transduction, cell 
proliferation and differentiation, vesicle transport, cancer progression and metastasis, angiogenesis 
and gene expression [238-248]. Clearly, these proteins play critical roles in many cellular 
processes.  
 
2.3.1 The Rho GTPases 
 
Since the discovery of the first Rho member Rhoa in 1985, from a low stringency cDNA screening 
[249], other members including Ras-related C3 botulinum toxin substrate 1 (Rac1) and Rac2 in 
1989 [250, 251], and cell division control protein 42 homolog (Cdc42) in 1990 were discovered 
[252]. To date, more than 18 members in eight distinct subfamilies have been reported [244], and 
of these three members of the family, RHOA, RAC1, and CDC42 [238, 249, 250, 253], have been 
extensively studied. The Rho proteins are virtually found in all eukaryotic species examined so 
far, and are highly conserved [241, 244, 247, 254-259]. In addition, given their close homology to 
Ras GTPases, the Rho GTPases act as molecular switches to regulate signal transduction pathways 
by alternating between an inactive GDP-bound state and an active GTP-bound conformational 
states. The activities of these proteins are primarily controlled by growth factors or integrins, and 
seven-transmembrane receptors [238, 239, 243, 244, 246, 254, 255, 258, 260-265]. 
 
2.3.2 Role of Rho GTPases in actin dynamics 
 
It is clear that the actin cytoskeleton drives many dynamic processes in cells, including migration, 
phagocytosis, endocytosis, vesicle trafficking to the plasma membrane, morphogenesis, and 
cytokinesis [238, 241-244, 247, 248, 250, 260, 266-270]. Further, depending on their biological 
function and location within the body, cells can acquire many shapes and forms. However, before 
a cell can undergo cellular processes like mitosis or locomotion, a degree of polarity is required 
[238, 244], which requires the cell to adopt a specific shape or direction rather than existing as an 
amorphous cell. Each member of the Rho family, i.e. RHO, RAC, and CDC42, is responsible for 
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specific regulation of actin dynamics [238, 244]. One of the most well-known morphological 
structure that is controlled by Rho proteins is the formation of lamellipodia and filopodia, which 
look like “sheets” or “fingers”, respectively, and aid in the propulsion and sensing across surfaces 
[238]. Rho GTPases are also responsible for the formation of stress fibers (originally thought to 
arise from the effects of tension) [241, 270], important in cell motility, contractility, and adhesion 
[243].  
 
2.3.2.1 Functions beyond actin dynamics  
 
Researchers working with Rho GTPases in the mid-1980s quickly realized their importance in 
actin dynamics. However, more recent work has demonstrated that Rho GTPases do much more 
than regulation of actin assembly, cell shape and migration. Over the last 20 years using a 
combination of techniques, such as: 1) use of dominant-negative mutants of Rho, 2) use of RAC 
and CDC42 toxins such as C3 (Rho inhibitor) or toxin B (RHO, RAC and CDC42 inhibitor), 3) 
analysis of transgenic model organisms, and 4) use of siRNA have demonstrated how critical each 
of these molecules are for the proper functioning of many cellular processes within a cell. Several 
lines of evidence seem to suggest that members of the Rho family can regulate a wide range of 
cellular functions including, cell-cell communication, gene expression, activation of the NADPH 
oxidase complex, maintenance of cell polarity, cell proliferation/differentiation, angiogenesis, and 
cancer progression and metastasis [113, 242, 246-248, 250, 254, 261, 262, 264, 269-282]. Signal 
transduction pathways from the Rho proteins have been also implicated in the regulation of gene 
transcription. For example, RHO is known to activate serum-response factor, whereas RAC1 and 
CDC42 activate the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways 
[244].  
 
2.3.3 Regulators of the Rho GTPases 
 
Under normal physiologic conditions, GTPases, including Ras and Ras-like proteins, are 
predominantly regulated at the post-translational level. Promoter analysis of the human Ras 
oncogene and Rac1 has revealed that the gene architecture resembles that of a housekeeping gene. 
The promoters lack regulatory elements, like the TATA box and CAAT box, have multiple 
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initiation start sites, and a rich CG content, with CpG islands surrounding the transcription 
initiation sites [283, 284]. However, use of in silico assays to study the promoter of the human 
Rac1 gene indicated consensus binding sites for several transcription factors, including E2F-4, as 
well as several zinc finger transcription factors, such as SP1, KLF15, MAZ, MZF1, PLAG1, and 
WT1 [285]. The discrepancies in these results could be due to the use of different human Rac1 
gene sequences, but clearly, further studies are needed. 
 
The post-transitional modifications that control intracellular signaling pathways regulated by Rho 
GTPases, act by affecting the state of the molecular switch. Alternating between GDP-bound and 
GTP-bound forms, affect the conformation of the GTP-binding switch 1 and switch 2 regions 
(Figure 2.7) [250, 254, 261, 264, 273, 274, 280, 286, 287]. The GDP-bound form is considered as 
the inactive state, whereas the GTP-bound state activates downstream pathways by binding to 
effectors. The cycling of Rho GTPases between the active/inactive states is regulated by three 
families of proteins, guanine nucleotide-exchange factors (GEFs), GTPase-activating proteins 
(GAPs) and guanine nucleotide-dissociation inhibitors (GDIs) [250, 254, 255, 261, 264, 273, 274, 
286]. GEFs, however, activate Rho GTPases, GAPs and GDIs act as inhibitors of the protein 
activity [244, 248, 255, 258, 260, 264, 287].  
 
Because GDP binds tightly and the GTPase capacity of the molecule is slow, small GTPases 
require GEFs to facilitate dissociation of GDP in exchange for a GTP molecule. Activated Rho 
GTPases are known to interact with close to 80 effector molecules (i.e. kinase, phospholipases, 
and scaffold proteins), which regulate downstream signaling events, including cell proliferation 
(by contributing to spindle orientation), differentiation (by regulating gene expression, and perhaps 
cell geometry and shape [288, 289]), cell migration (by affecting actin dynamics), and gene 
expression (via downstream protein-protein activation). Soon after the GTPase becomes active, 
GAPs associate with the protein and promote the GTPase activity leading to the hydrolysis of GTP 
to GDP [287]. Hence, the transition (or the molecular switch) between one state and the other is 
carefully balanced by the activation or suppression of GEFs and GAPs. Finally, the activity of Rho 
proteins can be further attenuated by their interaction with GDIs, which shields the hydrophobic 
tail that is incorporated in the C-terminus, and prevents the interaction with downstream effectors 
and confines the GTPase to the cytosol (Figure 2.7) [287]. The hydrophobic tail allows the 
23 
anchoring and incorporation of the GTPase into the cell membrane when active (Figure 2.7) and 
permits the interactions with effector proteins. Interestingly, not all known GTPases have the 
capacity to hydrolyze GTP [255, 260]. Other mechanisms regulating Rho GTPases also exist, i.e. 
phosphorylation, ubiquitination, and degradation, but these are minor, compared to those 
mentioned above. 
 
2.3.4 Rho GTPases and disease 
 
The founding member of the Ras superfamily was intensely studied during the 1980s, since it was 
found to be mutated in 30% of all human cancers. Further studies showed that a single amino acid 
substitution was responsible for the protein’s insensitivity to GAPs and therefore remained 
constitutively active [244]. Sequencing information derived from human cancers has uncovered 
no similar mutations in Rho GTPases. However, genetic alterations in the Rho GTPase signaling 
pathways have been reported in several human diseases. For instance, alterations in Rac2 gene 
sequence have been associated with immunological disorders such as leukocyte adhesion 
deficiency [245, 267, 290]. Similarly, other mutations in GAPs and GEFs have been reported [240, 
244, 291]. To date, Rac1 has been shown to be abnormally expressed in several tumor samples 
[203, 240, 265, 291]. Although there is evidence for polymorphism in the Rac1 gene sequence, 
most are intronic, and thus may not contribute to any genetic dysregulation [285]. However, a 
recent report has shown that a possible functional mutation due to a polymorphism in the Rac1 
gene could result in drug resistance [285]. In addition, an alternatively spliced variant of Rac1, 
Rac1b, containing an additional exon (exon 3b), and encoding a protein with 19 additional amino 
acid residues, has been described. Rac1b gene, primarily found in cancers [292-296], produces a 
functional GTPase that displays an increased intrinsic guanine nucleotide exchange rate [294] and 
a decreased intrinsic GTPase activity [294, 297] compared with those of RAC1.  
 
2.3.5 Ras-related C3 botulinum toxin substrate 1 (RAC1) 
 
Among the Rho GTPases, the subfamily of proteins named Rac (Ras-related C3 botulinum toxin 
substrate) has been most studied. There are four known Rac proteins (RAC1, 2, 3, and 1b), which 
display ~ 90% identity in their coding sequences and overall structure [250, 261, 268, 280], but 
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have different expression patterns. Whereas Rac1 is widely distributed in many cells [250, 251], 
Rac2 expression is mostly restricted to cells of the hematopoietic lineage [250, 290, 298], and 
Rac3 expression is in the brain, liver, and lung [268, 299]. Rac1b, the splice variant of exon 3 of 
Rac1, is detected primarily in cancerous cells [292-296]. Available protein sequences indicate that 
RAC1 is highly conserved among eukaryotes [241, 259], with high homology between mouse and 
human (Figure 2.8). 
 
RAC1 is known to play a fundamental role in a wide variety of cellular processes, which include 
actin cytoskeletal reorganization, cell transformation, angiogenesis, axonal guidance, and cell 
migration. More recently, researchers have begun to uncover new roles for RAC1 in a variety of 
physiological settings [7, 26, 255, 261, 266, 300-302]. Some of the physiologic functions that have 
been attributed to RAC1, include regulation of cell growth, vesicle trafficking, and generation of 
reactive oxygen species.  
 
Like other members of the Rho family of GTPases, RAC1 transduces extracellular signals from 
seven-transmembrane G-coupled protein receptors, integrins, and growth factor receptors to 
effector molecules that modulate multiple signaling pathways [260]. RAC1 can promote the 
activation of MAP kinase pathways and gene activation, however, its most important functions 
include the regulation of cytoskeletal structure and shape, resulting in important cell functions 
related to cell attachment, movement, and vesicle trafficking [248, 257, 260, 303-308]. Indeed, 
one of the primary functions of RAC1 is to promote the formation of the lamellopodium, which 
are sheet-like projections on the leading edge of a motile cell that propel the cell across a substrate 
[247, 248]. Furthermore, the action of RAC1 on actin fibers plays critical roles in vesicle transport. 
In dendritic cells, RAC1 induces actin-rich membrane protrusions during pinocytosis [309], which 
allows for antigen presentation, nutrient uptake, and sampling of the environment. RAC1 is also 
involved in phagocytosis by mediating localized polymerization of actin at the membrane to 
promote the internalization of attached particles and microorganisms [260]. In other cell types, 
RAC1 has been shown to regulate endocytic and exocytic trafficking pathways [247, 308]. Unlike 
CDC42, RAC1 is not involved in the early secretory pathway or membrane trafficking from the 
rER to the Golgi [308, 310]. However it does play a role in the later stages of secretion. RAC1 
regulates clathrin-dependent endocytosis [311] by modulating phosphatidylinositol-3 kinase 
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(PI3K) and synaptojanin 2, a novel RAC1 effector [312]. Phosphatidylinositol 4,5-bisphosphate is 
phosphorylated by PI3K to generate inositol triphosphate, which induces the activation of RAC1-
GEFs to regulate actin rearrangement and vesicular trafficking in various cell types [313]. 
Recently, PREX1, a PI3K-dependent Rac exchange factor, has been identified as a novel regulator 
of the glucose transporter 4 (SLC2A4/GLUT4) trafficking in adipocytes. PREX1 can activate 
RAC1, and this in turn stimulates actin polymerization and facilitates SLC2A4/GLUT4 transport 
to the plasma membrane [314]. Moreover, RAC1 can modulate clathrin-independent endocytosis 
by interacting with phosphatidyl-dependentinositol-4-phosphate5-kinase (PIP5K), via the 
polybasic region (PBR binding domain of RAC1). Calmodulin can also interact with RAC1 via 
the PBR and disrupt the interaction between RAC1 and PIP5K through steric hindrance [315]. 
 
RAC1 has also been reported to regulate calcium-dependent exocytosis in some cells. In neurons, 
a late step of Ca2+-dependent neurotransmitter release is regulated by RAC1 [316]. Activation of 
the RAC1 pathway in bovine chromaffin cells, transfected with human chorionic gonadotropin, 
led to an increase in secretion [317]. Similarly, in acinar cells of the pancreas, RAC1 can increase 
the secretion of amylase in response to cholecystokinin [318]. However, the precise mechanisms 
by which RAC1 pathways regulates exocytosis remain unknown. 
 
Another function of RAC1 that has received attention is its involvement in angiogenesis [203, 275, 
277, 319-326]. Hypoxia occurs in many cellular environments that are undergoing growth or 
differentiation. Oxygen homeostasis is critical for cell survival and in response to hypoxic 
conditions, cells activate the transcription of Hif1α to restore homeostasis [327-334]. Activation 
of HIF proteins stimulates the expression and production of Vegf, which drives angiogenesis and 
restores oxygen homeostasis [199, 205, 327, 329, 332, 333, 335]. Several lines of evidence have 
suggested that RAC1 regulates endothelial cell function by responding to VEGF [277, 323, 326]. 
Indeed, activation of the RAC1 pathway has been shown to enhance VEGF-induced 
neovascularization, whereas inhibition of this pathway prevents neovascularization in vitro [326]. 
Furthermore, activation of the RAC1 pathway in embryonic endothelial cells is critical for 
embryonic angiogenesis, and failure to do so, results in embryo death [277]. Additionally, in other 
cell systems such as pulmonary artery muscle cells, RAC1 can also stimulate Hif transcription 
[202-204, 280, 325] in a PI3K-dependent pathway [202-204, 280], and indeed Rac1 promoter 
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appears to contain HIF1α response element [325]. Collectively these studies raise the interesting 
possibility that RAC1 may play a role in uterine angiogenesis during early pregnancy by regulating 
the expression of VEGF, via a HIF-mediated manner. 
 
Although the cellular functions of RAC1 have been described in the literature, very little is known 
about their function in the endometrium, especially during pregnancy. Recent studies have 
suggested that RAC1 pathway is activated in human endometrial cells and may play a role in 
embryo attachment and invasion into the endometrium in the human [7, 26]. Furthermore, in the 
above studies, the authors concluded that the activation of the RAC1 pathway in the maternal 
decidual cells is necessary to allow invasion of the trophoblasts [7, 26]. However, due to the 
obvious ethical limitations, these studies were conducted in vitro and to the best of our knowledge, 
the role of RAC1 has not been explored in vivo.  
 
2.3.6 Available mouse models to study RAC1 function  
 
Despite the availability of mice carrying a global knockout mutation of Rac1 gene, these mice are 
not suitable to study the functional role of RAC1 in the uterus during early pregnancy. Global 
deletion of Rac1 leads to embryonic lethality around the time of during gastrulation [271]. 
Therefore, to overcome this limitation, we have developed a mouse model system that has 
provided us with the unique opportunity to study the functional and physiological role of RAC1 
pathway in the uterus. We have made use of the Cre-LoxP technology, to specifically target the 
deletion of Rac1 to specific tissues, thereby circumventing the embryonic lethality associated with 
the global knockout mutations of Rac1 [271]. This lethality is not seen in global knockouts for 
Rac2 [290] and Rac3 [299]. It should be noted that RAC2 and RAC3 mutants are fertile, and have 
not shown any indications of infertility or any other reproductive impairments [290, 299]. Our 
studies indicate that in contrast to RAC2 and RAC3, RAC1 plays a critical role in maintenance of 
pregnancy.  
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2.4 The aims of the dissertation 
To establish the functional role of uterine RAC1 during early events of pregnancy, I have used the 
PgrCre/+ Rac1f/f mouse model to specifically target Rac1 deletion in any tissue expressing Pgr, 
which includes the uterus. The following aims were established and are further discussed in this 
dissertation:  
Aim 1. Analyze the expression of RAC1 in the uterus during early pregnancy.  
1a. Determine the uterine cellular compartment that expresses RAC1 during early 
pregnancy. 
1b. Determine whether Rac2 and Rac3, the other members of the Rac subfamily, are 
expressed in the murine uterus during early pregnancy. 
Aim 2. Characterize the defects in fertility and identify the biological processes that prevent 
pregnancy maintenance in Rac1-null female mice.  
2a. Determine the timing of embryo demise in Rac1-ablated uteri during early pregnancy. 
2b. Perform an in depth analysis to determine whether conditional deletion of Rac1 in the 
murine uterus leads to improper stromal cell differentiation. 
2c. Investigate whether the deletion of uterine Rac1 impairs neovascularization in the 
endometrium during early pregnancy.  
2d. Determine whether conditional deletion of Rac1 prevents trophoblast migration and 
formation of placenta. 
Aim 3. Identify the pathways that mediate RAC1 function during decidualization. 
3. Perform gene expression profiling using endometrial RNA from control and Rac1-null 
uteri on day 8 of gestation to identify the RAC1-regulated pathways involved in 
angiogenesis during decidualization
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2.5 Chapter Figures 
 
 
 
 
FIGURE 2.1: HORMONE PROFILE DURING PREGNANCY IN MICE. Schematic representation of the critical events of pregnancy in mice and the 
hormone profile that accompany and regulate these events. The red line shows the hormone level for E2, whereas the blue line shows the hormone 
levels of P4. The inset picture, shows an embryo during the time of implantation attached to the luminal epithelium of the uterus.  
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FIGURE 2.2: COMPARISON OF THE EARLY EVENTS OF PREGNANCY IN HUMANS AND MICE. After fertilization, the zygote makes its way to the 
uterus, which takes about four days in mice and five to seven days in humans, prior to embryo implantation. For pregnancy timing in mice, our 
laboratory defines day 1 of pregnancy as the day of fertilization (others refer to it as E0.5). Around day 5 of pregnancy (in mice), and day 8 of 
pregnancy (in humans), the embryo begins the implantation process into the endometrium. Image adapted with permission from © 2001 Terese 
Winslow [336].  
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FIGURE 2.3: MORPHOLOGICAL CHANGES DURING STROMAL CELL DIFFERENTIATION. (A) Diagrammatic representation of the early and mid-
stages of pregnancy in mice. Image adapted with permission from [337]. AM = antimesometrial side; M = mesometrial side; E = embryo; PDZ = 
primary decidual zone (highlighted by dash-line); secondary decidual zone; DS = deep stromal cells. Images are at the same magnification.  
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FIGURE 2.3: MORPHOLOGICAL CHANGES DURING STROMAL CELL DIFFERENTIATION (CONTINUED). (B) Shown here are cross-sections of 
control uteri stained with hematoxylin and eosin at the beginning of embryo implantation and early stromal cells differentiation (day 4 midnight) 
and during the later stages of stromal cell differentiation (day 7 of pregnancy). In mice, embryo attachment and invasion occurs in the antimesometrial 
side of the uterus, i.e. the side opposite to the mesometrial ligament of the uterus, triggers the fibroblastic stromal cells to differentiate into an 
epitheloid and highly secretory decidual cells. Of note, decidualization does not occur at inter-implantation sites. AM = antimesometrial side; M = 
mesometrial side; E = embryo; PDZ = primary decidual zone (highlighted by dash-line); secondary decidual zone; DS = deep stromal cells. Images 
are at the same magnification.  
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FIGURE 2.4: MAJOR EVENTS DURING IMPLANTATION AND DECIDUALIZATION. Shown here are cross-sections of control uteri, on day 8 of 
pregnancy, stained for ALPL activity (blue staining), PRL8A2/dPRP (red staining enclosed by dash-line), and PECAM1/CD31 (red staining), which 
are well-known markers of the process of decidualization and vascular remodeling, respectively. AM = antimesometrial decidua; M = mesometrial 
decidua; E = embryo; LS = lateral blood sinusoid. Images are at the same magnification.  
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FIGURE 2.5: DEVELOPMENTAL STAGES OF THE MOUSE PLACENTA. Lineage specification and differentiation of the trophectodermal 
(extraembryonic) cells begin at on day 4 of pregnancy [embryonic day (E) 3.5] with the formation of the blastocyst. Around day 9 (E8.5) of 
pregnancy, chorion and allantois attach and this is followed by formation of the placental labyrinth, via branching morphogenesis. The mature 
(definitive) placenta is formed by day 15 (E14.5) of pregnancy, and it consists of three layers: the labyrinth, the spongiotrophoblast, and the maternal 
decidua. E0.5 = day 1 of pregnancy. AM = antimesometrial decidua; M = mesometrial decidua, Image adapted and modified with permission from 
[28]. 
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FIGURE 2.6: STRUCTURAL COMPARISON BETWEEN MEMBERS OF THE HUMAN RHO FAMILY OF GTPASES. The Rho family of GTPases (RHOA 
[338], RAC1 [339], and CDC42 [340]) are structurally similar to the prototype GTPase, RAS GTPase [341]. Three-dimensional images based on 
X-ray diffraction crystallography for these molecules were extracted, modified, and adapted from the NCBI Molecular Modeling Database [342]. 
  
35 
 
 
 
FIGURE 2.7: REGULATORY MECHANISMS OF THE RHO FAMILY OF GTPASES. 1) In the resting state cells, the non-activated GTPase is complexed 
with a guanine nucleotide dissociation inhibitor (GDI), which maintains the protein inactive in the cytosol by preventing the translocation to the 
plasma membrane. 2) Upon a signal, the GTPase is released from GTPase-GDI complex and the membrane association of the protein is promoted 
due to the hydrophobic tail in C-terminus. 3) At the same time, cycling between an inactive GDP-bound and an active GTP-bound mediated by 
interactions with a guanine nucleotide exchange factors (GEF). The activated membrane-associated proteins interact with downstream effectors to 
activate signal transduction pathways that lead to diverse cellular functions. 4) Association with GTPase activating proteins (GAPs) accelerates the 
hydrolysis of GTP, attenuating the activity of the GTPase. Once the cycle is complete and the protein is no longer needed, it will again form a 
complex with a GDI.  
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FIGURE 2.8: PROTEIN SEQUENCE COMPARISON BETWEEN HUMAN AND MOUSE RAC1. (A) Shown here is the comparison between the 192 amino 
acid protein sequence for human (GI 8574038) and mouse (GI 403115559) RAC1. As shown all 192 amino acid in the sequence match.  
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FIGURE 2.8: PROTEIN SEQUENCE COMPARISON BETWEEN HUMAN AND MOUSE RAC1 (CONTINUED). (B) The dot plot shows the graphical 
comparison between the two amino acid sequences. The “x”-axis represent each amino acids of the human RAC1 sequence and the “y”-axis shows 
those of the mouse RAC1 sequence. The protein sequences for human and mouse RAC1 were obtained from NCBI Protein and aligned using NCBI 
BLAST. The alignment and analysis were done using the onboard tool in BLAST [343, 344]. 
 
 
 
 
 
 
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: GENERATION AND PHENOTYPIC 
ANALYSIS OF RAC1D/D MUTANT 
FEMALE MICE  
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Abstract 
 
Members of the Rho GTPase family are pleiotropic signaling molecules that regulate a wide range 
of cellular processes, including cell cycle, cell differentiation, cell motility (through actin 
cytoskeleton remodeling), and angiogenesis. Recent in vitro studies suggested that one of the 
members of this superfamily such as Ras-related C3 botulinum toxin substrate 1 (RAC1), 
expressed by decidual cells, might be capable of influencing embryo implantation in the human. 
Although these studies suggested that RAC1 activity is critical for trophoblast invasion in vitro, it 
is not yet known whether RAC1 exhibits similar functions in vivo. Using a conditional deletion 
approach (Cre-loxP system), we generated transgenic mice that lack Rac1 gene expression and 
protein in uterine cells that are positive for progesterone receptor (PgrCre/+ Rac1f/f or Rac1d/d). Our 
results showed that conditional deletion of uterine Rac1 led to a severe subfertility phenotype. We 
observed more than 90% reduction in birth rate in Rac1d/d mice when compared to control Pgr+/+ 
Rac1f/f (Rac1f/f) female mice. Initial assessment of implantation nodules during early pregnancy 
(day 6 to 8) revealed that embryo attachment and gross morphology of implantation nodules were 
similar in the two genotypes. However, in depth histological analysis of uterine sections on day 8 
of gestation revealed dysregulation of stromal differentiation in the uteri of Rac1d/d mice. In 
response to aberrant stromal differentiation, we observed that between day 8 and 10 of pregnancy, 
a significant number of the implanted embryos became hemorrhagic and had begun to undergo 
resorption. By day 15 of pregnancy, most embryos had been lost and the few that survived, 
developed abnormal placentas and were surrounded by hemorrhagic maternal tissue. It should be 
noted that the fertility defect in Rac1d/d females is due to maternal shortcomings rather than an 
embryonic defect. Crossing of PgrCre/Cre Rac1f/f males x Pgr+/+ Rac1f/f females, which produced 
Rac1d/d embryos, resulted in viable offspring without pregnancy complications. Whereas a number 
of previous studies have shown that a defect in the embryo severely affects placentation and 
pregnancy outcome, we are reporting for the first time that a perturbation in the maternal 
differentiation program of Rac1d/d uteri adversely affects trophoblast function and maintenance of 
pregnancy. Future studies will address an in depth analysis of this new mouse model to improve 
our understanding of the cause and consequence of pregnancy complications in the human.  
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Introduction 
 
Implantation of the embryo to the uterine wall followed by placentation are pivotal events for 
establishment and maintenance of pregnancy [1-3, 110]. These processes involve steroid-
dependent complex crosstalk between the embryo and the maternal endometrium, which in turn 
supports the growing conceptus, and ensure reproductive success [2, 4, 5, 8, 107, 115]. Failure in 
any of the events can compromise maintenance of pregnancy and lead to miscarriage [5-7, 26, 32, 
143, 345]. In fact, clinically, implantation failure and spontaneous abortion following implantation 
are among the leading causes of infertility in women of reproductive age and reveals a major 
challenge for assisted reproductive technology [6, 7, 38, 39]. In many instances the reasons for 
implantation failure are unknown. 
 
In rodents, as the embryo breaches the luminal epithelium following attachment, the underlying 
stromal cells undergo a dramatic transformation to form a specialized tissue, known as the decidua 
[5, 23, 25, 29, 117, 154, 346]. During decidualization, the fibroblastic stromal cells proliferate and 
then differentiate into mature secretory decidual cells that support embryo growth and survival 
until placentation [23-25, 29, 121-123]. In addition, the decidual tissue undergoes extensive 
remodeling to accommodate the growing embryo. Concomitant with the differentiation process, 
as the decidua forms around the implanted embryo, endothelial cells in the uterine stroma 
proliferate to create an extensive vascular network, which is embedded in the decidua and is critical 
for embryo development [5, 23, 25, 29, 32, 117, 154, 346]. It is clear that decidualization is a key 
event in establishment of early pregnancy, however, the signaling molecules that participate in the 
formation and function of this tissue remain poorly understood.  
 
Microarrays are powerful molecular tools that allow rapid screening of gene expression changes 
under different experimental conditions. Using this tool, we compared differentially expressed 
genes in the uterus during decidualization and identified Ras-related C3 botulinum toxin substrate 
1 (RAC1) as one of the genes whose expression is markedly elevated at the time decidualization. 
While a previous study performed in vitro, implicated a potential role of RAC1 in embryo invasion, 
its role in vivo during implantation remains unknown [7, 26]. We, therefore, decided to explore 
the in vivo function of RAC1 in the uterus during early pregnancy.   
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RAC1, a pleiotropic signaling molecule and a member of the Rho family of GTPases, has been 
shown to regulate many cellular processes. These include cell cycle, cell-cell adhesion, cell 
differentiation, cell motility through actin cytoskeleton remodeling, endothelial cell function, as 
well as angiogenesis [113, 242, 250, 254, 261, 262, 269, 271-280, 301]. Because decidualization 
encompasses many of these physiological events, it is possible that RAC1 regulates one or more 
of these processes during early pregnancy. In support of this notion, Grewal et al. [7, 26] has shown 
recently that invasion of the human embryo into endometrial stroma, in vitro, involves the motility 
of endometrial stromal cells and this movement is dependent on the activity of Rho GTPases, 
especially RAC1. Here, we show that RAC1 is necessary for early pregnancy, as uterine loss of 
this molecule led to severe subfertility. However, contrary to the previous in vitro observations, 
we now show that RAC1 activity is not necessary for embryo attachment or invasion into the 
uterine stroma to initiate embryo implantation.    
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Materials and Methods 
 
Animals and Tissue Collection 
 
All animal breeding, housing, procedures, experiments, and euthanasia were approved and 
conducted according to the guidelines of the Institutional Animal Care and Use Committee of 
University of Illinois at Urbana-Champaign. The health and care of the animals was provided by 
the veterinarians and staff of Division of Animal Resources. Rac1 conditional null mice were 
generated using Cre-LoxP strategy [347] (Figure 3.1A). Mice expressing homozygous copies of 
the Rac1 gene flanked by loxP sites [Pgr+/+ Rac1f/f (official gene symbol Rac1tm1Djk/J), or Rac1f/f 
from now onwards] [267] were obtained from Dr. Ann Sutherland (University of Georgia) in a 
C57BL/6-129SV background. Mice carrying the Cre Recombinase under the control of the 
progesterone receptor (Pgr) promoter [348] [PgrCre/+ Rac1+/+ (official gene symbol Pgrtm2(cre)Lyd/+), 
or PgrCre from now onward], were obtained from Drs. John Lyndon and Francesco De Mayo 
(Baylor College of Medicine) in a C57BL/6 background. To establish the mouse colony for this 
study, initial breeding between the two mouse lines was done to obtain the F1 progeny, which are 
heterozygous for Pgr and Rac1 (Appendix A). Female mice used for this study were generated by 
breeding male mice of specific genotypes from the F2 progeny (see Figure 3.1B) with Rac1f/f 
female mice. Genotyping of the animals was performed following the protocols established by the 
respective laboratories that generated the transgenic mice [267, 348] (Appendix A). Conditional 
knockout female mice (PgrCre/+ Rac1f/f) will be referred to as Rac1d/d from now onwards. 
 
Rac1f/f or Rac1d/d females were euthanized by CO2 asphyxiation, followed by a blood draw via 
cardiac puncture, and cervical dislocation. Uteri and ovaries from pregnant mice or from mice 
subjected to experimentally-induced decidualization (see below) were collected at different time 
points during pregnancy or following the differentiation stimulus. The harvested organs were 
either fixed for histological evaluation [immersion-fixed in 10% neutral-buffered formalin (NBF)], 
flash frozen in liquid N2 for RNA or frozen sectioning, or the decidual mass was harvested for 
gene expression studies. For samples collected at different time points during pregnancy, 
identification of a copulatory plug following mating was used as a reference and for our 
experimental purposes, to indicate day 1 of pregnancy. 
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Some of the frozen implantation nodules, collected on day 8 of pregnancy, were thawed by 
submerging them in 1x phosphate-buffer saline (PBS) at room temperature for morphological 
evaluation of the decidua. The decidual mass was exposed by mechanical removal of the 
myometrium. Pictures were taken using a Leica M165 FC dissection scope connected to a Leica 
450 C camera with c-mount interface containing a 5 Megapixel CCD sensor. Similarly, for 
morphological evaluation of embryos on day 15 of pregnancy, mechanical removal of the 
myometrium was done on samples that had been fixed in 10% NBF under the dissecting scope, as 
mentioned above. 
 
Fertility testing  
 
To determine whether conditional mutation of Rac1 in uterine tissues had any effect in female 
fertility, Rac1f/f and Rac1d/d mice of reproductive age (8 weeks or more) were paired with proven 
wild-type males for a period of six months (Appendix A). The total number of pups born in each 
litter as well as the number of pregnancies during this period were recorded. 
 
Experimentally-induced decidualization 
 
To test whether RAC1 plays any role during decidualization, 8 week old female mice were 
subjected to experimentally induced decidualization protocol as described previously [32, 154, 
349-352]. Briefly, adult, non-pregnant, Rac1f/f and Rac1d/d female mice were ovariectomized under 
general anesthesia and rested for two weeks following ovariectomy to remove any circulating 
hormones. After two weeks of rest, the animals were injected subcutaneously (s.c.) with 100 ng of 
17β-estradiol (E2) in 100 µL corn oil daily for three days, then rested for two days. Following 
resting period, mice were injected with a solution containing 6.7 ng E2 and 1 mg P4 per 100 µL 
(E2 + P4) corn oil s.c. for three days. On the third day of E2 + P4 injection, decidualization was 
initiated, under general anesthesia, in one horn by injection of 50 μL oil, whereas the other horn 
was left unstimulated to serve as an internal control. Daily injections of E2 + P4 were continued 
for up to an additional 96 h post-stimulation. Mice were euthanized and uterine horns were 
collected and weighed at different time points following the decidualization stimulus. 
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Hormonal treatment 
 
To test whether Rac1 gene expression is affected by hormonal treatment, Rac1f/f mice were 
subjected to different doses of steroid hormones as described previously [353]. Briefly, female 
mice were subjected to bilateral ovariectomy. Two weeks later, the mice were injected 
subcutaneously with 100 µL of vehicle (oil), E2 (100 ng), P4 (1 mg) or combination of E2 + P4. 
The animals were then euthanized at 6 h and 24 h following E2 alone; after 2 doses daily of P4; or, 
in case of the combination, 2 daily doses were given, followed by E2, then tissue was collected 6h 
and 24 h after the last injection.  
 
Alkaline Phosphatase Activity Assay 
 
The protocol for detecting alkaline phosphatase (ALPL) activity was followed as previously 
published [352, 354], with modifications. Briefly, frozen uterine sections were incubated in 10% 
NBF for 10 min at room temperature then washed in 1x PBS three times for 5 min each (3x 5 min.) 
The slides were then incubated with a solution containing 0.1 M Tris-HCl pH 8.5, 0.5mM naphthol 
AS-MX phosphate disodium salt (ALPL substrate), and 1.5 mM fast blue RR (4-benzoylamino-
2,5-dimethoxyaniline diazonium) salt at 37 oC for 30 min. The uterine alkaline phosphatase 
activity releases orthophosphate and naphthol derivatives from the substrate. The naphthol 
derivatives are simultaneously coupled with diazonium salt present in the incubating medium to 
form a dark blue dye, which marks the site of enzyme action. To terminate the enzymatic reaction, 
the tissue sections were rinsed in tap water, mounted using crystal mount medium, and visualized 
using an Olympus BX51 microscope equipped for light microscopy connected to a Jenoptik 
ProgRes C14 digital camera with c-mount interface containing a 1.4 Megapixel CCD sensor. 
 
Immunohistochemistry and Immunofluorescence  
 
Paraffin-embedded or frozen uterine sections were subjected to immunohistochemistry as 
described previously [32, 353, 355, 356]. Briefly, paraffin-embedded sections were deparaffinized 
in xylene and rehydrated in a series of graded alcohols followed by rinsing in tap water. When 
frozen tissues were used, the sections were thawed at room temperature for 5 min, then fixed for 
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another 5 min in 10% NBF. Sections were then rinsed in 1x PBS, followed by blocking in 10% 
non-immunized serum for 1 h at room temperature. The slides were incubated with a solution 
containing the diluted antibody (see Appendix E for details) and 1% serum in 1x PBS overnight at 
4 oC in a humidified chamber. Following overnight incubation, slides were washed 3x 5 min with 
1x PBS, then incubated with diluted secondary antibody (see Appendix E for details) for 1 h at 
room temperature in a humidified chamber. When a chromogenic labeling was done, sections were 
incubated in a solution containing 3% H2O2 in methanol to quench endogenous peroxidase. Slides 
were then rinsed in 1x PBS, followed by a 30-45 min incubation with horseradish peroxidase-
conjugated streptavidin (Invitrogen). Slides were then exposed to chromogens (3, 3’-
diaminobenzidine or 3-amino-9-ethylcarbazole) until optimal signal was obtained. Following the 
chromogenic labeling, the slides were counterstained with hematoxylin, and mounted. Slides that 
were incubated with a fluorescent secondary antibody were mounted with a medium containing 
DAPI. Pictures were taken using the Olympus BX51 microscope equipped for light and fluorescent 
imaging and connected to a Jenoptik ProgRes C14 digital camera with c-mount interface 
containing a 1.4 Megapixel CCD sensor. Fluorescent images were merged and processed using 
CS4 Adobe Photoshop Extend (Adobe Systems). 
 
RNA Isolation and Real-time quantitative PCR  
 
Total RNA was isolated from tissues or cells using TRIzol reagent (Invitrogen) according to the 
manufacturer’s instructions. Oligonucleotides specific for genes of interest were developed (see 
Appendix F for details) and real-time quantitative PCR (qPCR) reactions were carried out using 
SYBR-green master mix (Applied Biosystems) on a 7500 Applied Biosystems Real-time PCR 
machine. Gene expression data analysis were done using the 2-ΔΔCt method [357] and 36b4 gene – 
which is conserved among many species and encodes an acidic ribosomal phosphoprotein P0 that 
interacts with 40S ribosomal subunit – was used as a housekeeping gene and loading control [358].  
 
Endometrial Stromal Cell Isolation 
 
Endometrial stromal cells were isolated from day 1 and 4 pregnancy samples as previously 
described [164, 352]. Uteri were removed from mice after euthanasia with CO2. The uteri were cut 
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open and digested with a solution containing 6 g/L dispase (Gibco) and 25 g/L pancreatin (Sigma) 
in 1x HBSS (Gibco) for 45min at room temperature, followed by 15 min at 37 oC, with occasional 
mixing. Cells were washed and then incubated in 0.5 g/L collagenase (Sigma) in HBSS for 1 h at 
37 oC. After incubation, the tubes were vortexed for 10-12 seconds until the supernatant became 
turbid with dispersed cells. The contents of the tube were then passed through an 80-μm gauze 
filter (Millipore) into a new tube. Cells were resuspended in Dulbeccos modified Eagle's medium-
F12 medium (Gibco) supplemented with 2% heat-inactivated fetal calf serum, 100 units/L 
penicillin, 0.1 g/L streptomycin (Gibco), 1.25 mg/L fungizone, 10 nM E2, and 1 µM P4. The 
numbers of live cells were assessed by trypan blue staining using a hemocytometer. 
 
Western Blots 
 
Mouse endometrial stromal cells or decidual masses were isolated from female mice at different 
days of pregnancy. The cells from day 1 and 4 pregnant uteri were lysed in ice-cold lysis buffer 
containing 1% NP40, 50 mM Tris-HCl pH 7.6, 125 mM NaCl, 1 mM EDTA, 1x protease inhibitor 
cocktail. Decidual mass on D8 of pregnancy was lysed with lysis buffer aided by maceration using 
a mortar and pestle. The cell debris was removed by centrifugation, and the protein concentration 
of the lysate was determined by bicinchoninic acid protein assay according the manufacturer's 
instruction (Pierce/Thermo/Fisher Scientific). The cell lysates were analyzed by standard Western 
blotting, using antibodies against RAC1 (1:1000) and β-TUBULIN (1:5000, as loading control, 
see Appendix E for antibody details).  
 
Hormone assay 
 
Serum P4 concentrations were measured for at least 3 animals per time point by radioimmunoassay 
at the core facility of University of Virginia at Charlottesville.  
 
Statistical analysis 
 
Experimental data were collected from a minimum of three independent animals (not from the 
same litter). Uterine weights, serum hormones, embryo perimeter, placental weight, and qPCR 
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results were expressed as mean ± S.E.M. Litter size were expressed as means. Statistical analysis 
was done using Student’s t-test (for single comparison), one-way analysis of variance with a 
Dunnett’s post-test (for multiple comparison between treatments or time points) or two-way 
ANOVA with a Bonferroni post-test (for multiple comparison between different genotypes and 
time points). An analysis of equal variances was done on all numerical data to determine whether 
a parametric or non-parametric hypothesis test was appropriate. Data were considered statistically 
significant at p ≤ 0.05, and is indicated by an asterisk in the figures. All data was analyzed and 
plotted using GraphPad Prism 4.0 (GraphPad Software).  
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Results and Discussion 
 
Rac1 is expressed in uterine stroma during decidualization, but its expression is independent of 
steroid hormones 
 
To gain insight into the molecular pathways underlying decidualization, we performed gene 
expression profiling using RNA from uterine horns at different times after exposure to decidual 
stimulation. Our studies revealed upregulation of Rac1 in response to decidual stimulation. To 
confirm the results of the microarray analysis, we performed qPCR using RNA isolated from the 
non-stimulated and stimulated horns at different times after decidual stimulation. As shown in 
Figure 3.2A, Rac1 expression increased in response to decidual stimulation. A marked increase in 
Rac1 expression was observed at 72 h post decidual stimulation. Consistent with this expression 
profile, we observed a significant upregulation in Rac1 expression during normal pregnancy on 
day 7 and day 8 of gestation (Figure 3.2B).  
 
Because steroid hormones, estrogen (E2) and progesterone (P4) are known to influence 
decidualization, we investigated whether Rac1 gene expression is regulated by steroid hormones. 
Administration of E2, P4, or E2 + P4 to ovariectomized mice failed to induce Rac1 expression in 
the uterus, indicating that it is not regulated by steroid hormones (Figure 3.2C). Interestingly, 
previous studies have indicated the presence of response elements for several transcription factors, 
including HIFs, in the Rac1 promoter [285]. It is possible that HIFs, which are induced during 
stromal differentiation, are involved in the regulation of Rac1 in the uterus during early pregnancy. 
However, further analysis of the Rac1 promoter during stromal cell differentiation will be needed 
to validate this possibility.  
 
We next monitored by western blot analysis the expression profile of RAC1 protein in the uterus 
at different days of gestation. We observed a band corresponding to RAC1 protein on day 4 of 
gestation. But consistent with the RNA profile, we observed a marked enhancement in RAC1 
protein expression in uterine stromal cells on day 8 of pregnancy, overlapping the window of 
decidualization (Figure 3.2D). Interestingly on day 8, we also noted the presence of a band 
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corresponding to phosphorylated RAC1 (pRAC1) in the western blot. The functional significance 
of pRAC1 in the uterus remains unknown.  
 
The Rac1d/d mouse model  
 
To address the role of RAC1 in the uterus, we generated a mouse line where the Rac1 gene is 
conditionally deleted using a Cre recombinase that is under the control of one copy of the 
progesterone receptor promoter (termed PgrCre/+), whereas the other copy expresses functional 
Pgr, which is sufficient to preserve fertility of these animals [348]. The conditional deletion 
approach was used because the Rac1 global knockout is embryonic lethal [271]. Further, PgrCre 
mouse line has been extensively used to ablate genes in specific cells lineages within the body [32, 
345, 348, 353, 359-361]. Rac1 gene is conditionally excised in only those tissues that are positive 
for Pgr, which includes the uterus. The term Rac1f/f and Rac1d/d will be used to refer to the control 
and conditional null mice, respectively.  
 
Ablation of Rac1 in the Rac1d/d mice was assayed by qPCR and our studies indicate efficient 
ablation of Rac1 in the uteri on day 4 to day 10 of pregnancy (Figure 3.3A). Consistent with the 
RNA profile, we observed a marked decline in the levels of RAC1 protein in Rac1d/d uteri on day 
4 or day 8 of gestation (Figure 3.3B). Our results also indicate that the gene expression of other 
members of the Rho family of GTPases, such as Rac2, Rac3, Rhoa, and Cdc42, were unaffected 
upon conditional deletion of Rac1 (Figure 3.3C). 
 
Conditional deletion of uterine Rac1 leads to severe subfertility 
 
To determine the role of RAC1 in the regulation of fertility, a six-month breeding study was 
performed by crossing Rac1d/d or Rac1f/f mice with proven wild-type males (see Appendix A for 
details). At the completion of the study, we noted a severe subfertility phenotype in Rac1d/d female 
mice compared to Rac1f/f controls. More than 90% of the pups were lost during pregnancy 
indicating a drastic reduction in the litter size (Table 2.1). In addition, most Rac1d/d females 
exhibited a drastic reduction in their fertility rate after the first pregnancy (data not shown), and 
many females did not produce any litters after the second or third pregnancy. Although these 
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results are of interest to us, we have not investigated this issue any further as part of this dissertation 
project.  
 
Conditional deletion of Rac1 has no effect on ovarian function 
 
Because progesterone receptor is transiently expressed in the granulosa cells of the ovary around 
the time of ovulation [362-366], and given that RAC1 is ubiquitously expressed in many cell types, 
it is conceivable Rac1 may be deleted from the ovary, resulting in insufficient ovarian function. 
Therefore, to ensure that the severe subfertility phenotype, and pregnancy loss, observed in Rac1d/d 
mice was not due to an ovarian defect, ovaries from days 4, 8, 10 (data not shown), 12, and 15 of 
pregnancy were collected and evaluated histologically for signs of anovulation or lack of corpora 
lutea (CL) (Figure 3.4). Ovaries collected from Rac1d/d females displayed follicles at all stages of 
development and CL with normal appearance (Figure 3.4A). Moreover, we monitored Rac1 gene 
expression in the ovary on day 4 of pregnancy, and consistent with the ovarian histology data, 
there was no significant difference in Rac1 mRNA expression in the ovaries from Rac1f/f and 
Rac1d/d mice (Figure 3.4B). We also determined the serum progesterone concentrations in the two 
genotypes to ensure that the fertility defect was not due to a deficiency in circulating P4. Indeed, 
no significant difference was found in serum P4 concentration between Rac1
d/d and Rac1f/f mice 
(Figure 3.4C). Moreover, we did not detect any significant difference in the average number of 
blastocysts recovered from the uteri of Rac1f/f and Rac1d/d mice on day 4 of pregnancy (data not 
shown). 
 
We next investigated the effect of deletion of uterine Rac1 on embryo implantation. Previous 
studies by Grewal et al. [7, 26] suggested that activation of the RAC1 pathway in the decidual cells 
is required for implantation and trophoblast invasion and expansion. Interestingly, our studies 
revealed that uterine deletion of Rac1 gene did not prevent attachment of the embryos into the 
maternal endometrium (Figure 3.5A). We noted the presence of implanted embryos in the uterus 
beginning on day 4 of pregnancy and, up to day 8 of pregnancy, we did not detect any overt 
abnormality of the implantation nodules in the two genotypes. Interestingly, a closer histological 
examination of uterine sections on different days of gestation revealed that starting on day 7, the 
embryos in Rac1d/d mice started to display abnormality at the implantation site and this became 
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more pronounced on day 8 of pregnancy. Staining of uterine sections on day 8 with cytokeratin, 
which marks the trophoblast cells showed aberrant overexpansion of trophoblast cells in maternal 
stroma (Figure 3.5B and Appendix C). At this time, we have not fully characterized the 
overexpansion phenotype of the embryos. However, it is possible that the dysregulated trophoblast 
expansion could be a result of improper differentiation of uterine stroma due to ablation of RAC1.  
 
A number of previous studies have implicated RAC1 as a regulator of critical cellular processes, 
including cell proliferation and differentiation [242, 261, 269, 273, 276, 280, 301, 367]. Because 
stromal cell differentiation is a critical event for establishment of pregnancy, we determined 
whether conditional deletion of uterine Rac1 affected this process by employing a well-established 
differentiation model that is independent of the embryo [154]. We observed that the gross decidual 
response in Rac1d/d uteri was comparable to that of control Rac1f/f uteri (Figure 3.6, lower panel).  
 
During decidualization, stromal cells proliferate, exit the cell cycle, and terminally differentiate 
into mature decidual cells [346, 368-372]. The progression of this differentiation program can be 
traced by monitoring the expression of biochemical markers in the uterus. As cells enter the 
differentiation program, they express liver/bone/kidney alkaline phosphatase (ALPL) (Figure 2.3). 
We further investigated the decidual response in Rac1f/f and Rac1d/d uteri by monitoring the 
expression of ALPL. As expected, uterine sections from Rac1f/f mice displayed prominent ALPL 
activity at 48 h after the administration of decidual stimulus (Figure 3.6B, upper panel). 
Interestingly, we noted a dramatic induction of ALPL activity in Rac1d/d uteri at similar time point, 
indicating dysregulated stromal differentiation program in the absence of uterine RAC1 (Figure 
3.6B, lower panel).  
 
We next examined the role of RAC1 in stromal decidualization during normal pregnancy. We did 
not observe any difference in cell proliferation on day 8 of pregnancy, as indicated by MKI67 
staining (Figure 3.7C). However, consistent with the observation that the stromal differentiation 
program is dysregulated by the loss of uterine RAC1, we noted a marked upregulation in Alpl gene 
expression (Figure 3.7A) as well as activity (Figure 3.7B) in Rac1d/d uteri in comparison to Rac1f/f 
controls. We also examined the expression of other markers of differentiation including Wnt4 and 
Prl8a2/dPrp during decidualization (Figures 3.7 and Appendix B). While the expression of Wnt4 
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was upregulated (Figure 3.7A) in Rac1d/d uteri, we observed a slight downregulation in the 
expression of PRL8A2/dPRP protein (Figure 3.7D) in uterine sections of Rac1d/d mice compared 
to Rac1f/f controls on day 8 of pregnancy. A reduction in Prl3c1/Plpj gene expression was also 
noted (Figure 3.7A). PRL3C1/PLPJ has been reported to be produced by the decidual cells 
immediately surrounding the embryo [373] and may be implicated in decidual cell development 
and the endometrial vasculature [374] around day 8 of pregnancy. We also monitored the 
expression of Alpl and Wnt4 in cultured stromal cells collected from Rac1f/f and Rac1d/d uteri on 
day 4 of pregnancy and subjecting them to in vitro decidualization. Again, similar to the pregnancy 
samples, our results revealed a marked enhancement in Alpl and Wnt4 expression in stromal cells 
from Rac1d/d uteri (Figures 3.8). Collectively, these results indicate that in the absence of uterine 
RAC1, the stromal differentiation program during pregnancy goes awry. 
 
The severe subfertility in Rac1d/d is due to maternal but not embryonic defect 
 
How do we rule out the possibility that the subfertility in Rac1d/d mice is not due to an inherent 
defect in the embryo? A number of previous studies have shown that a defect in the embryo 
severely affects trophoblast migration and placentation [9, 59, 129, 130, 132, 300]. However, to 
the best of our knowledge, only a limited number of mouse models exist in the literature in which 
a perturbation in the maternal decidua, and not the embryo, adversely affects trophoblast function 
and placentation [32, 359, 360, 375-378]. In that regard, the Rac1d/d mice are unique. Thus, to 
avoid any complication of potential non-specific deletion of Rac1 gene in the embryo, we bred the 
Rac1d/d and Rac1f/f females to wild-type male mice of proven fertility. This breeding scheme 
generated heterozygous embryos for Rac1 gene (see Appendix A for details), therefore any 
problems associated with pregnancy are likely due to a defect in the maternal decidua, and not in 
the embryo or its membranes. Our breeding studies further indicated that embryo loss occurred 
around day 10 to 12 of pregnancy, and appear as hemorrhagic implantation nodules (Figures 3.9 
and 3.10A). It should be noted, however, that not all embryos died at this time point. A small 
percentage of the embryos managed to survive to later stages of gestation (Figure 3.10C), and even 
to be born (Table 3.1). It is intriguing that some embryos managed to survive, whereas others die. 
One observation we have consistently made is that there is a cleft that remains in the uteri of 
Rac1d/d mice (Figure 3.10B), possibly from defective migration of decidual cells. In Rac1d/d uteri, 
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this area is highly hemorrhagic and many neutrophils infiltrate the luminal space of the cleft, while 
a thin decidua surrounds the embryo in the mesometrial side (data not shown). An interesting 
possibility is that in Rac1d/d uteri, the decidua fails to form an immune barrier from the allogenic 
embryo [23, 29, 149-151], resulting in embryo resorption and termination of pregnancy.  
 
Studies performed in the early 1990s showed that the mouse blastocyst expresses detectable Pgr 
mRNA expression [379]. However, we ruled out any possibility that a potential deletion of Rac1 
in the embryonic tissues adversely influenced the outcome of pregnancy because of the following 
reasons. First, heterozygous females for both Rac1 and PgrCre (PgrCre/+ Rac1f/+) are fertile (Table 
3.2), and when bred to either PgrCre/+ Rac1f/f or PgrCre/Cre Rac1f/f males they 1) produced litters 
with the expected genotypes (based on genetic expectancy of the crossing; see Appendix A for 
details); 2) they produced viable offspring, which were later used for breeding purposes; and 3) 
pups with a PgrCre/Cre Rac1f/f genotype were generated in this crossing. In addition, crossing of 
Rac1f/f females with either PgrCre/+ Rac1f/f, PgrCre/Cre Rac1f/f, or Pgr+/+ Rac1+/+ males of proven 
fertility, showed that Rac1f/f females carrying Rac1d/d embryos were fertile and produced viable 
litters (Figure 3.11), strongly suggesting that the fertility defect observed in the mutant females is 
due to a maternal rather than an embryonic defect. Collectively, these results indicate that the 
maternal environment due to dysregulated stromal differentiation in Rac1d/d uteri is not conducive 
to embryo growth. In the next chapter, we have investigated how impaired stromal differentiation 
is affecting maternal environment leading to embryo demise in uteri lacking RAC1.  
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Chapter Figures and Tables 
 
 
 
 
 
 
 
 
 
FIGURE 3.1: BREEDING SCHEME TO GENERATE THE CONDITIONAL MUTANT FOR RAC1 USING CRE-LOXP STRATEGY. (A) The gene construct 
for Rac1 gene and the primer position for genotyping strategy are shown. Floxed and wild-type bands are detected with the primer combination 
P91/P33, whereas the conditional knockout band is detected with the primer combination P45/P33 [347]. Triangles indicate the LoxP sites. 
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FIGURE 3.1: BREEDING SCHEME TO GENERATE THE CONDITIONAL MUTANT FOR RAC1 USING CRE-LOXP STRATEGY (CONTINUED). (B) The 
breeding scheme for the generation of the experimental animals is shown. Briefly, male mice, with specific genotypes, were bred to Rac1f/f females 
to generate the conditional mutant. In these animals, exon 1, which contains the translation initiation site and part of the GTPase activity of RAC1, 
will be conditionally excised in all cells that express Pgr gene. 
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FIGURE 3.2: EXPRESSION PROFILE FOR RAC1 GENE AND PROTEIN IN MICE. (A – C) Whole uterus gene expression profile for Rac1 after 
experimentally-induced decidualization (panel A), hormonal stimulation (panel B), and during pregnancy (panel C). (D) RAC1 protein expression 
profile from isolated endometrial stromal cells on day 4 of pregnancy or decidual cells on day 8 of pregnancy; day 1 shows a similar profile as day 
4 of pregnancy (data not shown). As expected, both gene and protein increase in expression during cell differentiation, but are unaffected by hormonal 
treatment alone. n ≥ 3 per time point. Asterisks indicate significant differences from 0 h on panel A or day 1 of pregnancy in panel B (p < 0.01). 
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FIGURE 3.2: EXPRESSION PROFILE FOR RAC1 GENE AND PROTEIN IN MICE (CONTINUED). (A – C) Whole uterus gene expression profile for Rac1 
after experimentally-induced decidualization (panel A), hormonal stimulation (panel B), and during pregnancy (panel C). (D) RAC1 protein 
expression profile from isolated endometrial stromal cells on day 4 of pregnancy or decidual cells on day 8 of pregnancy; day 1 shows a similar 
profile as day 4 of pregnancy (data not shown). As expected, both gene and protein increase in expression during cell differentiation, but are 
unaffected by hormonal treatment alone. n ≥ 3 per time point. Asterisks indicate significant differences from 0 h on panel A or day 1 of pregnancy 
in panel B (p < 0.01). 
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FIGURE 3.3: RAC1 IS EFFICIENTLY DELETED FROM THE UTERUS USING PGRCRE. (A) Whole uterus gene expression profile demonstrates an 
efficient knockdown of Rac1 gene in Rac1d/d mice in samples obtained at different times during pregnancy. (B) RAC1 is efficiently ablated in 
endometrial stromal cells on day 4 of pregnancy, as well as on decidual cells on day 8 of pregnancy. Residual RAC1 protein may come from 
contamination from other cell populations (like uterine natural killer cells), which migrate into the uterus around day 8 of pregnancy.  
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FIGURE 3.3: RAC1 IS EFFICIENTLY DELETED FROM THE UTERUS USING PGRCRE (CONTINUED). (C) Whole uterus gene expression profile on day 
8 of pregnancy shows that Rac1 is the only member that is affected by the conditional deletion; other members of the Rho family of GTPases are 
not affected by the conditional deletion. n ≥ 3 per time point. Asterisks indicate significant differences from controls (**, p < 0.01, ***p < 0.001). 
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TABLE 3.1: IMPACT OF RAC1 DELETION ON FEMALE FERTILITY 
Genotype # Females † # Pups # Litters 
Average  
Pups/Litter
 ‡ 
Pgr
+/+ 
Rac1
f/f
 7 315 31 10 
Pgr
Cre/+ 
Rac1
f/f
 7 19 11 2 
 
    
† One Rac1
d/d
 female did not produce any litters during or after the breeding study 
‡ p < 0.0001   
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FIGURE 3.4: CONDITIONAL DELETION OF RAC1 DOES NOT AFFECT OVARIAN FUNCTION. (A) Representative histological samples of ovaries from 
Rac1f/f and Rac1d/d on days of pregnancy (D) 4, 8, 12, and 15 stained with H&E. No differences in the ovarian morphology were observed at these 
time points. Bars = 200 µm.  
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FIGURE 3.4: CONDITIONAL DELETION OF RAC1 DOES NOT AFFECT OVARIAN FUNCTION (CONTINUED). (B) Consistent with the observation in 
Panel A, no significant difference ovarian was observed in Rac1 gene expression by D4. (C) Serum progesterone (P4) concentration was unaffected 
by the conditional deletion of Rac1. n = 3 per time point. (p > 0.05). 
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FIGURE 3.5: CONDITIONAL DELETION OF RAC1 HAS DOES NOT PREVENT EMBRYO ATTACHMENT AND INVASION INTO THE ENDOMETRIUM. (A 
and B) Shows representative samples from Rac1f/f and Rac1d/d on day 8 of pregnancy. No gross morphological difference was observed between 
conditional null and control mice (panel A).  
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FIGURE 3.5: CONDITIONAL DELETION OF RAC1 HAS DOES NOT PREVENT EMBRYO ATTACHMENT AND INVASION INTO THE ENDOMETRIUM 
(CONTINUED). (A and B) Also, uterine deletion of Rac1 gene does not prevent embryo implantation (panel B). CYTOKERATIN 8 was used as a 
general marker of trophoblast cells to highlight the implanted embryo. Bars = 500 µm. n ≥ 5. 
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FIGURE 3.6: CONDITIONAL DELETION OF UTERINE RAC1 DOES NOT AFFECT THE FORMATION OF THE DECIDUOMA, BUT DISPLAYS 
DYSREGULATION IN ALPL ACTIVITY. (A) No difference was detected in the wet weight of the deciduoma induced experimentally in conditional 
Rac1-null mice compared to controls (p > 0.05). Shown here are representative sample after 96 h post stimulus uteri. The right horn was stimulated, 
whereas the left horn served as an internal control and was not stimulated. (B) Conditional deletion of uterine RAC1 led to a dysregulated increase 
in the activity of the early marker of decidualization, kidney/liver/bone alkaline phosphatase (ALPL) activity at all the observed time points. Shown 
here is uterine ALPL activity 48 h post stimulus. n = 3 per time point.  
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FIGURE 3.7: CONDITIONAL DELETION OF RAC1 LEADS TO A DYSREGULATED STROMAL CELL DIFFERENTIATION. (A) Gene expression assay 
was done on day 8 of pregnancy to access the expression of well-known makers that are differentially expressed during stromal cell differentiation. 
Critical genes that are known to be expressed during the early stages of differentiation, i.e. Alpl and Wnt4, show a dysregulated gene expression. 
Prl3c1/Plpj a putative marker of late stromal cell differentiation was reduced (p = 0.14), as compared to control uteri. Other genes involved in the 
differentiation of stromal cells, were not significantly changed at this time point of pregnancy. Asterisks indicate significant differences from controls 
(**, p < 0.01, ***p < 0.001).  
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FIGURE 3.7: CONDITIONAL DELETION OF RAC1 LEADS TO A DYSREGULATED STROMAL CELL DIFFERENTIATION (CONTINUED). (B) Alkaline 
phosphatase (ALPL) activity is a well-known indication of early stromal cell differentiation, and persist during the differentiation of stromal cells. 
Our data show that there is noticeable elevation in both Alpl gene expression (panel A) and activity in day 8 pregnancy samples. Similar observations 
were made on day 7 of pregnancy (data not shown). Bars = 500 µm. 
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FIGURE 3.7: CONDITIONAL DELETION OF RAC1 LEADS TO A DYSREGULATED STROMAL CELL DIFFERENTIATION (CONTINUED). (C & D) It is 
well established that during the differentiation process, decidualizing stromal cells rapidly proliferate and quickly enter the differentiation program 
[346, 368-372]. Our data indicate that stromal cell from Rac1d/d uteri are capable of initiating the differentiation into decidual cells, as no difference 
in MKI67 (panel C), a maker of cell proliferation. However, despite no change in gene expression, uteri deficient for Rac1 display a reduced 
expression of PRL8A2/dPRP (panel D), a marker of late stromal cell differentiation, when compared to control uteri. The area below the dash mark 
indicate the area negative for MKI67, which positive cells have a reddish/brown nuclear staining. Bars = 200 µm (panel C and D). 
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FIGURE 3.7: CONDITIONAL DELETION OF RAC1 LEADS TO A DYSREGULATED STROMAL CELL DIFFERENTIATION (CONTINUED). (C & D) It is 
well established that during the differentiation process, decidualizing stromal cells rapidly proliferate and quickly enter the differentiation program 
[346, 368-372]. Our data indicate that stromal cell from Rac1d/d uteri are capable of initiating the differentiation into decidual cells, as no difference 
in MKI67 (panel C), a maker of cell proliferation. However, despite no change in gene expression, uteri deficient for Rac1 display a reduced 
expression of PRL8A2/dPRP (panel D), a marker of late stromal cell differentiation, when compared to control uteri. PRL8A2/dPRP is highlighted 
by the cells with a red cytoplasmic stain under the dash mark. Bars = 200 µm (panel C and D). n ≥ 4. 
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FIGURE 3.8: ACTIVATION OF THE DECIDUAL CELL RAC1 PATHWAY IS NECESSARY FOR STROMAL CELL MORPHOLOGY AND NORMAL 
DIFFERENTIATION. Shown here are cultured uterine decidual cells, under differentiation conditions for 72 h. As shown here, cells, where Rac1 gene 
has been deleted (Rac1d/d), show abnormal cell morphology, compared to control cells (Rac1f/f). Similarly, during the differentiation of decidual 
cells, gene expression of factors, likes alkaline phosphatase (Alpl) and Wnt4 are known to be expressed, but shown here is a dysregulated gene 
expression of these factors in the mutant decidual cells; other factors, like decidual prolactin-related protein (Prl8a2/dPRP) gene expression remain 
unchanged. Blue = DAPI, which stains the nucleus, and green = Phalloidin, which stains actin filaments. n = 3. Asterisks indicate significant 
differences from controls (p < 0.001). 
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FIGURE 3.9: REPRESENTATIVE UTERI SAMPLES AT DIFFERENT STAGES OF PREGNANCY. Uteri samples at different times of pregnancy were 
collected from Rac1f/f and Rac1d/d on days 8 through 15 of pregnancy. Black arrows point hemorrhagic implantation nodules, whereas blue arrow 
head highlight lateral hemorrhage, which commonly seen in hemochorial placentation. n ≥ 3. 
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FIGURE 3.10: SEVERE HEMORRHAGE IS OBSERVED IN IMPLANTATION NODULES FROM RAC1D/D UTERI. (A) The graph shows a survival curve 
analysis of the onset of hemorrhagic uteri collected from day 4 of pregnancy. Hemorrhagic implantation nodules are typically noticed as early as 
day 7 of pregnancy.  
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FIGURE 3.10: SEVERE HEMORRHAGE IS OBSERVED IN IMPLANTATION NODULES FROM RAC1D/D UTERI (CONTINUED). (B) Shown here are 
representative samples of pregnancy nodules on day 8 of pregnancy from control, conditional knockout, and heterozygous uteri after the nodules 
were liberated from the myometrium to expose the decidua. Severe hemorrhage is typically observed in the conditional knockout decidua, whereas 
the control and heterozygous uteri appear do not display this severe bleeding. Bars = 10 mm.  
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FIGURE 3.10: SEVERE HEMORRHAGE IS OBSERVED IN IMPLANTATION NODULES FROM RAC1D/D UTERI (CONTINUED). (C) Representative samples 
implantation nodules on day 15 of pregnancy from control and conditional knockout females after the nodules were liberated from the rest of the 
uterine horn to expose each embryo and the placenta (P). Severe hemorrhage are observed in nodules obtained from conditional knockout uteri, 
whereas the control uteri appear do not show signs of hemorrhaging. Also, note that the placenta of the conditional knockout female have many 
focal hematoma (H), and this is typically observed in these females. Of note, the hemorrhage observed in the pregnancy nodule originates from small 
hemorrhages in the maternal tissues (M) surrounding the placenta and chorioallantoic membranes (CA) of the embryo. Once the maternal layers are 
removed and the fetal chorioallantoic membranes are exposed, no hemorrhage is observed. Bars = 5 mm. n ≥ 3. 
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TABLE 3.2: SINGLE OR EPITHELIAL-SPECIFIC RAC1 ALLELE DELETION DOES NOT IMPACT FERTILITY 
Genotype # Females # Pups # Litters 
Average 
Pups/Litter
 ‡
 
Pgr
+/+ 
Rac1
f/f
 7 307 31 10 
Pgr
Cre/+ 
Rac1
f/f
 7 19 11 2 
Pgr
Cre/+ 
Rac1
f/+
 2
†
 76 12 6 
Wnt7a
Cre/+ 
Rac1
f/f
 3 141 15 9 
 
         
† The data shown represent the breeding performance over a six-month period. Different from the Rac1
f/f
,
 
Rac1
d/d
, and Wnt7a
Cre/+
 Rac1
f/f
 females, the 
data collected for Pgr
Cre/+
 Rac1
f/f
 (heterozygous) females was from the current breeding colony, where these females are paired to Pgr
Cre/Cre 
Rac1
f/f 
or 
Pgr
Cre/Cre 
Rac1
f/+ 
males, not wild-type males. 
 
         
‡
 
This table is for comparison purposes only. Because of the limitation in samples of heterozygous, appropriate statistical analysis could not be 
performed. Data collected from Wnt7aCre females were collected at a time PgrCre and control females. Data from heterozygous females was 
collected from the available data from the breeding colony, which at the time was experiencing breeding problems. Nonetheless, the data here show 
that heterozygous females are fertile and capable of producing viable litters.  
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FIGURE 3.11: PREGNANCY DEFECT OBSERVED IN RAC1 CONDITIONAL-NULL UTERI IS NOT DUE TO AN EMBRYONIC DEFECT. (A) To determine 
if the potential expression of Pgr in the blastocyst is sufficient to produce any of the defects that are seen in Rac1d/d females, uteri were collected 
from control (Pgr+/+ Rac1f/f) female mice on day 8 of pregnancy after they were mated with either homozygous Cre (PgrCre/Cre Rac1f/f), floxed (Pgr+/+ 
Rac1f/f), or wild-type (Pgr+/+ Rac1+/+) male mice. Homozygous Cre males bred to control females produce offspring that have the same genotype as 
the conditional null mice (PgrCre/+ Rac1f/f), while wild-type males bred to control females, produce offspring that are similar to the experimental 
conditions of the mating for this study (Pgr+/+ Rac1f/+). In all, the gestation nodules collected were normal, without any alteration to the expected 
uterine gross morphology.  
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FIGURE 3.11: PREGNANCY DEFECT OBSERVED IN RAC1 CONDITIONAL-NULL UTERI IS NOT DUE TO AN EMBRYONIC DEFECT (CONTINUED). (B) 
Uteri in panel A were further dissected and representative implantation nodules, and the correspondent decidual masses and embryos are shown. No 
morphological perturbations were observed. Bars = 1 mm. n ≥ 2 per genotype 
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CHAPTER 4: RAC1 IS A CRITICAL REGULATOR OF 
UTERINE ANGIOGENESIS DURING 
EARLY PREGNANCY IN THE MOUSE 
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Abstract 
 
In mice, following implantation, the uterine stromal cells differentiate into specialized decidual 
cells, which support the growth of the embryo before placentation. Concomitantly, new blood 
vessels begin to form in the maternal decidua from pre-existing vasculature through angiogenesis, 
an absolutely critical event for the establishment of placenta and maintenance of pregnancy. It is 
clear that decidualization and angiogenesis play crucial roles during early gestation, however, the 
complex molecular pathways underlying these processes remain unknown. Our recent studies 
revealed that Rac1 (Ras-related C3 botulinum toxin substrate 1), a pleiotropic signaling factor, is 
induced in uterine stroma during decidualization and may play a role in regulating this process. To 
address the role of RAC1 during pregnancy, we generated a conditional knockout of the Rac1 gene 
in the uterus by crossing mice carrying floxed Rac1 with PgrCre mice. A six-month breeding study 
indicated a severe defect in fertility of the Rac1-ablated (Rac1d/d) females. Further analysis showed 
hemorrhagic uteri starting on day 7 of pregnancy and by day 10 of gestation, resorption of embryos 
was clearly evident. An in depth analysis showed dysregulation of the stromal differentiation 
program during decidualization in Rac1d/d uteri. Interestingly, the loss of Rac1 expression in 
uterine stromal cells also resulted in a marked impairment in the development of maternal blood 
vessels as indicated by the expression of PECAM1/CD31, Hif2α, Angpt2, and NRP1. This uterine 
angiogenic defect is, presumably, one of the main contributors to pregnancy loss seen in Rac1d/d 
mice at mid-gestation. Based on these results, we propose that RAC1 controls the differentiation 
of stromal cells to decidual cells, which produce critical local factors that impact on blood vessel 
formation at the maternal-fetal interface during early pregnancy. 
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Introduction 
 
Decidual neovascularization, the process by which new blood vessels originate from pre-existing 
vessels, during the post-implantation period is an absolute requirement for pregnancy maintenance 
in humans and rodents [73]. Indeed, it is thought that the newly formed uterine vasculature during 
decidualization functions as an early site of nutrient and gas exchange for the developing embryo, 
until the placenta becomes functionally competent [57, 74]. Although the details underlying the 
process of decidualization and angiogenesis are slightly different between humans and rodents, the 
basic sequence of events and many of the molecular pathways that regulate these processes are 
similar between the two species. 
 
In the pregnant uterus, angiogenesis is a critical process that precedes placentation, and requires 
signals that originate from the embryo and the endometrium [1, 5, 9, 10, 29, 32, 75-77, 360]. 
Among the many signaling molecules, hypoxia-inducible transcription factor (HIF), vascular 
endothelial growth factor (VEGF), and angiopoietins (ANGPTs) play major roles in endometrial 
vascular remodeling during decidualization. Interestingly, hypoxia is a detectable feature in the 
uterine environment during embryonic development [199-201]. Oxygen homeostasis is critical for 
cell survival and in response to hypoxic conditions, cells activate the transcription of Hif1α to 
restore oxygen homeostasis [206, 207, 327-334]. Activation of HIF stimulates Vegf expression, 
which promotes angiogenesis [203, 205, 327, 329, 332, 333, 335]. Several lines of evidence 
suggest that under hypoxic conditions, RAC1 regulates endothelial cell function by responding to 
VEGF signaling [323]. Activation of the RAC1 pathway, using a dominant active form of RAC1, 
has been shown to enhance VEGF-induced neovascularization, whereas inhibition of RAC1 
activity prevents neovascularization in vitro [326]. Further, activation of RAC1 in embryonic 
endothelial cells is critical for embryonic angiogenesis, and global mutations of RAC1 lead to 
defective vascularization and embryonic death [277]. Interestingly, in other cell systems such as 
pulmonary artery muscle cells, RAC1 has been shown to stimulate Hif transcription [202-204, 280, 
325] via the PI3K-dependent pathway [202-204, 280]. Collectively, these studies raise the 
interesting possibility that RAC1 may play a role in angiogenesis in decidual tissues by regulating 
VEGF expression. 
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To gain an insight into the pathways that are affected by the ablation of Rac1 in uterine stroma and 
lead to termination of pregnancy, we performed gene expression profiling of decidual RNA 
collected from Rac1-intact and Rac1-null uteri on day 8 of gestation. We focused on day 8 because 
severe hemorrhage and embryo loss occur by day 10 of pregnancy, suggesting that the processes 
that are leading to embryo demise are most likely arising on day 8 of pregnancy. Consistent with 
RAC1’s role in angiogenesis, our studies revealed that RAC1 is a critical regulator of this process 
in the uterus. Ablation of uterine RAC1 led to a dysregulation in vascular network formation in 
the maternal decidual bed due to defective expression and secretion of pro-angiogenic factors. 
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Materials and Methods 
 
Animals and Tissue Collection 
 
All animal breeding, housing, procedures, experiments, and euthanasia were approved and 
conducted according to the guidelines of the Institutional Animal Care and Use Committee of 
University of Illinois at Urbana-Champaign. The health and care of the animals was provided by 
the veterinarians and staff of Division of Animal Resources. Rac1 conditional null mice were 
generated using Cre-LoxP strategy [347] (Figure 3.1A). Mice expressing homozygous copies of 
the Rac1 gene flanked by loxP sites [Pgr+/+ Rac1f/f (official gene symbol Rac1tm1Djk/J), or Rac1f/f 
from now onwards] [267] were obtained from Dr. Ann Sutherland (University of Georgia) in a 
C57BL/6-129SV background. Mice carrying the Cre Recombinase under the control of the 
progesterone receptor (Pgr) promoter [348] [PgrCre/+ Rac1+/+ (official gene symbol Pgrtm2(cre)Lyd/+), 
or PgrCre from now onward], were obtained from Drs. John Lyndon and Francesco De Mayo 
(Baylor College of Medicine) in a C57BL/6 background. To establish the mouse colony for this 
study, initial breeding between the two mouse lines was done to obtain the F1 progeny, which are 
heterozygous for Pgr and Rac1 (Appendix A). Female mice used for this study were generated by 
breeding male mice of specific genotypes from the F2 progeny (see Figure 3.1B) with Rac1f/f 
female mice. Genotyping of the animals was performed following the protocols established by the 
respective laboratories that generated the transgenic mice [267, 348] (Appendix A). Conditional 
knockout female mice (PgrCre/+ Rac1f/f) will be referred to as Rac1d/d from now onwards. 
 
Rac1f/f or Rac1d/d females were euthanized by CO2 asphyxiation, followed by a blood draw via 
cardiac puncture, and cervical dislocation. Uteri from pregnant mice were collected at different 
time points during pregnancy. The harvested organs were either fixed for histological evaluation 
[immersion-fixed in 10% neutral-buffered formalin (NBF)], flash frozen in liquid N2 for RNA or 
frozen sectioning, stromal cell isolation, or decidual mass was harvested for gene expression 
studies. For samples collected at different time points during pregnancy, identification of a 
copulatory plug following mating was used as a reference and for our experimental purposes, to 
indicate day 1 of pregnancy. 
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For microarray analysis, decidual nodules from day 8 of pregnancy were isolated following blood 
perfusion, as previously described [380-382]. Briefly, day 8 pregnant mice were anesthetized with 
ketamine-xylazine cocktail (87 mg ketamine; 15 mg xylazine / kg body weight). After the mice 
were unconscious, a V-shape incision expanding radially to the chest was made so that the uterus, 
liver, and ribs were visible. The chest cavity was opened and the heart was exposed. Immediately, 
the mouse was perfused through the left ventricle of the heart, while the blood drained through the 
right atrium, with at approximately 20 mL of Hank’s balanced salt solution containing heparin 
(HBSS+H , 30 USP Units / mL) until the liver and uterine implantation nodules were visually 
cleared of blood. Following perfusion, the uterine horns were dissected and placed in HBSS+H 
for separation of the decidual mass. With the use of a dissection microscope (Leica M165 FC), the 
uterine myometrium was mechanically removed with jeweler forceps and the decidual mass 
containing the embryo was excised. Once all the masses were separated from the muscle, they 
were transferred into a new 35 mm dish with fresh HBSS+H to remove any leftover blood and the 
embryo. To remove the embryo, the isolated decidual mass was rotated so that one of the two 
mesometrial indentations was visible. Then, using the indentation as a guide, the decidua was 
carefully opened and the embryo was removed from antimesometrial side by carefully lifting it 
out of the decidual mass. The decidual masses, freed from the embryos, were transferred to a new 
35 mm dish with fresh HBSS+H for a final rinse before collected and flash frozen for further RNA 
isolation. Four decidual masses/animal were collected for microarray analysis.  
 
Microarray and expression analysis 
 
Total RNA was extracted from the isolated and perfused decidual masses with TRIzol (Invitrogen) 
following the manufacturer's protocol. The RNA preparations were then purified with the RNeasy 
kit (Qiagen). Samples were stored in RNase-free water until further use. To evaluate the purity and 
quality of the isolated RNA, the samples were submitted to the Roy J. Carver Biotechnology 
Center (at the University of Illinois) for assessment of RNA quality and chip hybridization for 
microarray analysis. Quality of the RNA samples were assessed using an Agilent Bioanalyzer 
System and samples with a RNA integrity number of 10 were used for microarray analysis using 
a GeneChip Mouse Genome 430A 2.0 Array (Affymetrix), containing approximately 14,000 
annotated gene sequences. Subsequently, the chips were scanned and the data were extracted using 
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Gene-Chip Operating Software version 1.3 (Affymetrix), which later were exported to Microsoft 
Excel 2013 (Microsoft Corporation). Expression values for each gene below 50 was considered as 
background. Relative gene expression fold value was determined by the ratio of gene expression 
of Rac1d/d decidua to Rac1f/f decidua. A list of genes that had a relative fold change of +/- 1.5, were 
further analyzed for gene ontology and functional classification using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID, National Institute of Allergy and Infectious 
Diseases, National Institutes of Health) [383].  
 
Quantitative PCR gene validation and RNA isolation 
 
Total RNA was isolated from whole uterine samples, as reported above. RNA was converted to 
cDNA using a kit (Applied Biosystems), according to the manufacturer’s instructions. 
Oligonucleotides specific for genes of interest were developed (see Appendix F for details) and 
real-time quantitative PCR (qPCR) reactions were carried out using SYBR-green master mix 
(Applied Biosystems) on a 7500 Applied Biosystems Real-time PCR machine (Applied 
Biosystems). Gene expression data analysis were done using the 2-ΔΔCt method [357] and 36b4 
gene – which is conserved among many species and encodes an acidic ribosomal phosphoprotein 
P0 that interacts with 40S ribosomal subunit – was used as a housekeeping gene and loading 
control [358].  
 
Immunohistochemistry, Immunocytochemistry, and Immunofluorescence  
 
Cultured cells, paraffin-embedded or frozen-sectioned uterine sections were subjected to 
immunohistochemistry or immunocytochemistry as described previously [32, 353, 355, 356]. 
Briefly, paraffin-embedded sections were deparaffinized in xylene and rehydrated in a series of 
graded alcohols followed by rinsing in tap water. When frozen tissues were used, the sections were 
thawed at room temperature for 5 min, then fixed for 5 min in 10% NBF at room temperature. If 
cells were used, they were fixed for 5 min in 10% NBF at room temperature. Sections or cells were 
then rinsed in 1x phosphate-buffer saline (PBS), followed by serum blocking using 10% non-
immunized serum for 1 h at room temperature. Following serum block, slides were incubated with 
a solution containing the diluted antibody (see Appendix E for details) and 1% serum in 1x PBS 
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overnight at 4 oC in a humidified chamber (for slides) or in the culture plate (for cells). Following 
overnight incubation, slides were washed 3 times, 5 min each, with 1x PBS, then incubated with 
diluted secondary antibody (see Appendix E for details) for 1 h at room temperature. When 
chromogenic labeling was done, the samples were incubated in a solution containing 3% H2O2 in 
methanol to quench endogenous peroxidase. Samples were then rinsed in 1x PBS, followed by a 
30-45 min incubation with horseradish peroxidase-conjugated streptavidin (Invitrogen). The 
samples were then exposed to chromogens (3, 3’-diaminobenzidine or 3-amino-9-ethylcarbazole) 
until optimal signal was obtained. Following the chromogenic labeling, the samples were 
counterstained with hematoxylin and mounted. When immunofluorescence was done, the samples 
were incubated with a fluorescent secondary antibody were mounted with a medium containing 
DAPI. Pictures were taken using the Olympus BX51 microscope equipped for light and fluorescent 
imaging and was adapted to a Jenoptik ProgRes C14 digital camera with c-mount interface 
containing a 1.4 Megapixel CCD sensor or an Olympus Ix70 inverted microscope adapted to 
Diagnostic Instrument digital camera containing a 2.0 Megapixel CCD sensor. Fluorescent images 
were merged and processed using CS4 Adobe Photoshop Extend (Adobe Systems). 
 
Primary endometrial stromal cell isolation and culture 
 
Endometrial stromal cells were isolated, from three independent mice per genotype on day 4 of 
pregnancy as previously described [164, 352]. Briefly, uteri were removed from mice after 
euthanasia with CO2. The uteri were flushed with 200 – 300 µL of HBSS to remove embryos and 
to confirm pregnancy. Then, the uteri were cut open and digested with a solution containing 6 g/L 
dispase (Gibco) and 25 g/L pancreatin (Sigma) in 1x HBSS (Gibco) for 45min at room 
temperature, followed by 15 min at 37 oC, with occasional mixing. The enzyme activities were 
quenched by adding equal volumes of 10% FBS solution, then cells were washed three times with 
1x HBSS (Gibco). Cells were then incubated in 0.5 g/L collagenase (Sigma) in HBSS for 1 h at 
37 oC. After incubation, the tubes were vortexed for 10-12 seconds until the supernatant became 
turbid with dispersed cells. The contents of the tube were then passed through an 80-μm gauze 
filter (Millipore) into a new tube. Cells were resuspended and plated for cell culture in Dulbeccos 
modified Eagle's medium-F12 medium (Gibco) supplemented with 2% heat-inactivated fetal calf 
serum, 100 units/L penicillin, 0.1 g/L streptomycin (Gibco), 1.25 mg/L fungizone, 10 nM E2, and 
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1 µM P4. The numbers of live cells were assessed by trypan blue staining using a hemocytometer. 
Cells were plated for 2 hours at a density of 5 x 105 cell/well in 6-well culture plates to allow 
stromal cells, but not epithelial cells, to attach. After the 2 hour incubation (0 h of culture), the 
medium was aspirated and the cells were rinsed with two to three changes of fresh media, until 
most of the unattached cells were removed. Media were again changed at 24 h (and stored for a 
baseline reading) and 48 h after the initial change (0 h). Following the 48 h media change, the cells 
were cultured for up to 96 h from the initial plating (0 h), and media were collected in 24 h 
intervals. The media from three-wells were pooled and collected at 24, 72, and 96 h time point, 
and the cellular debris was removed via centrifugation, and stored for ELISA. In addition, the cells 
were collected by rinsing with HBSS followed by incubation with 0.25% trypsin at 37 oC until the 
cells detached. The cells and media were stored at -80 oC until needed. The numbers of live cells 
were determined using trypan blue staining and a hemocytometer, then, the cells were placed in 
TRIzol reagent (Invitrogen) for further RNA isolation. 
 
Measurement of vascular-endothelial growth factor A (VEGFA) in culture medium 
 
Measurements of VEGFA production in vitro were done from pooled media from three wells (from 
a 6-well plate, Corning) from at least three independent cell cultures (one culture = one animal), 
plated at an initial density of 5x105 cell/well. Enzyme-linked immuno sorbent assay (ELISA) for 
mouse VEGF were done according to the manufacturer recommendations (R&D Systems).  
 
Statistical analysis 
 
Experimental data were collected from a minimum of three independent animals (not from the 
same litter), which were subjected to the same experimental conditions. ELISA and qPCR results 
were expressed as mean ± S.E.M. Statistical analysis was done using Student’s t-test. An analysis 
of equal variances was done in all numerical data to determine whether a parametric or non-
parametric hypothesis test was appropriate. Data were considered statistically significant if p ≤ 
0.05, and is indicated by an asterisks in the figures. All data were analyzed and plotted using 
GraphPad Prism 4.0 (GraphPad Software) or Microsoft Excel 2013 (Microsoft Corporation).  
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Results and Discussion 
 
Microarray analysis reveals impaired angiogenic network in Rac1-ablated uteri 
 
We previously established that the severe subfertility phenotype observed in the Rac1d/d female 
mice was due to a defect in maternal environment. Our studies also revealed that embryo loss 
occurred between days 10 to 12 of pregnancy in Rac1d/d females, suggesting that the disruption of 
events preceding these dates are critical for maintenance of gestation. During this window, several 
biological processes are known to occur in the uterus. These include ongoing differentiation of the 
decidual cells, extensive vascular remodeling and angiogenesis [23, 31, 57, 166, 167], trophoblast 
proliferation and invasion into the endometrium, as well as formation of the placenta [5, 9, 28, 78, 
112, 126, 128, 129, 131-133] (Figures 1.4 and 1.5). We employed the microarray approach to 
identify the genes and the regulatory pathways that might be affected by Rac1 deletion in the 
endometrium. The microarray analysis was performed by isolating RNA from decidua of Rac1-
intact and Rac1-null uteri on day 8 of pregnancy.  
 
Out of the approximately 14,000 well-characterized genes that were analyzed in the 430A 
microarray chip, 1345 genes were differentially regulated (± 1.5 fold). Out of the differentially 
regulated genes, 796 were down-regulated in Rac1-null decidua compared to Rac1-intact controls. 
Gene ontology was performed by using NIH DAVID for analysis [383]. We identified multiple 
biological processes, including angiogenesis, which appeared to be regulated by RAC1 in the 
decidua during pregnancy (Figure 4.1).  
 
The expression of several genes that are known to play major roles in neovascularization in the 
endometrium during early pregnancy were affected by the loss of RAC1 [32, 194, 384]. Validation 
of the microarray data showed that expression of these genes including hypoxia-inducible factor 2 
alpha (Epas1/Hif2α) [207, 385], angiopoietin 2 (Angpt2), and Angpt4 were markedly reduced in 
the absence of uterine expression of Rac1 (Figure 4.2). The expression of other genes involved in 
angiogenesis, including sphingosine kinase 1 (Sphk1), neuropilin 1 (Nrp1), and the clotting factor 
XIII subtype A1 (F13a1) were also attenuated by the loss of uterine Rac1 (Figure 4.2). 
Intriguingly, however, the expression of hypoxia-inducible factor 1 alpha (Hif1α) and vascular-
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endothelial growth factor A (Vegfa), which are well known regulators of angiogenesis (Figure 4.3), 
remained unchanged. Nonetheless, the significant alterations in transcription of genes associated 
with uterine angiogenesis led to a marked reduction in vascular network formation, as noted by 
the reduced expression of platelet endothelial cell adhesion molecule 1 (PECAM1/CD31) on day 
8 (Figure 4.4A) or day 10 of pregnancy (Figure 4.4B).  
 
Whereas the expression of Vegf was unaltered, we observed a marked downregulation of 
angiopoietin 2 in the absence of RAC1 in the uterine stroma. Angiopoietins, acting on the 
angiopoietin receptor, TEK/TIE2, work along with VEGF to promote new blood vessel formation 
from pre-existing ones [30, 58, 63, 64, 72, 180, 184, 197]. Interestingly, decidual tissues of women 
with recurrent miscarriages show imbalance in the expression ratio of Angpt2 and Angpt1, to favor 
Angpt1 rather than Angpt2 [63], which is predominant during uterine angiogenesis. ANGPT2 plays 
a role in branching angiogenesis, which may be involved in the development of complex vascular 
network seen in the uterus during pregnancy [58, 63, 64]. Although the precise role of 
angiopoietins in uterine angiogenesis remains unknown, previous studies have shown that genetic 
deletion of Angpt2 causes capillary dysmorphogenesis in the kidney [386], as well as abnormal 
patterning of the blood vessels of the retina in mice [387].  
 
The actions of VEGF are mediated through several receptors, primarily VEGFR1/FLT1 and 
VEGFR2/ FLK1. VEGFs can also activate neuropilin receptors including NRP1 [168, 178, 184, 
185]. Our studies revealed that along with Angpt2, neuropilin 1 gene and protein expression was 
severely compromised in the absence of uterine Rac1 (Figures 4.2 and 4.5). Previous studies have 
shown that in response to VEGF stimulation, NRP1 plays a role in guidance of neuronal and 
endothelial cells during the process of neurogenesis, which is usually accompanied by 
angiogenesis [388, 389]. Studies have also shown that mutant embryos, deficient for Nrp1, display 
disorganization of the vasculature, without affecting the formation of primary vascular network or 
differentiation of endothelial cells [390]. The fact that Nrp1 is significantly downregulated in the 
decidua (Figure 4.5), suggests that migration and proliferation of endothelial cells might be 
affected in the uteri of Rac1d/d mice. It is possible that during decidualization, RAC1-dependent 
pathways in the maternal stroma are involved in the regulation of endothelial cell reorganization.  
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Ablation of Rac1 in the uterus leads to a decreased secretion of pro-angiogenic factors 
 
To gain insights into the underlying mechanisms of the angiogenic defect observed in Rac1d/d 
females, we used a well-established in vitro cell culture system of decidualization [164, 352]. 
Stromal cells isolated from Rac1-intact and Rac1-null uteri cultured in vitro showed distinct 
differences in morphology and architecture as indicated by staining for F-actin using phalloidin 
(Figure 3.7). It is known that actin cytoskeletons regulate certain aspects of vesicle trafficking and 
protein secretion [248, 255, 257, 260, 308, 314, 316, 391, 392]. Indeed, one of the described 
functions of RAC1 is to promote the formation polymerization of actin fibers to regulate vesicle 
transport [247, 255, 263, 308, 314, 391]. We, therefore, explored the possibility that RAC1 may 
be involved in secretion of proteins such as VEGFA in decidual cells. We analyzed the protein 
expression of VEGFA by immunocytochemistry in cultured mouse endometrial stromal cells that had 
been subjected to decidualization in vitro. Our results show that Rac1-null cells display an impaired 
vesicular transport of VEGFA. Stromal cells from conditional knockout uteri displayed an 
accumulation of VEGFA in the cellular compartment where Golgi/rER are normally located within the 
cell (Figure 4.6A). Consistent with this observation, measurement of VEGFA in the supernatant of 
mature decidual cells revealed a significant reduction in VEGFA production and secretion in Rac1-
null cells (Figure 4.6). Vegfa gene expression, however, was similar in Rac1-intact and Rac1-null 
stromal cells. The precise stage at which RAC1 regulates the secretory activity of decidual cells 
warrants further investigation. However, previous data has implicated RAC1 in trafficking secretory 
vesicles from the Golgi to the plasma membrane [308, 310, 314]. Thus, it is highly possible that 
RAC1’s actions are at the final stages of vesicular transport.  
 
It is believed that RAC1 is not involved in the early stages of secretory pathway (i.e. rER to Golgi) 
[310], nor has it been localized to the rER membrane. However, RAC does play a role in the later 
stages of secretion. Recently, PREX1, a PI3K-dependent Rac exchange factor, has been identified 
as a novel regulator of the glucose transporter 4 (SLC2A4/GLUT4) trafficking in adipocytes. 
PREX1 can activate RAC1, and this in turn stimulate actin polymerization and facilitate 
SLC2A4/GLUT4 transport to the plasma membrane [314]. Additionally, RAC1 has also been 
reported to regulate exocytosis in a calcium-dependent manner [316, 318, 392]. The precise 
mechanisms and the cellular compartments in which RAC1 elicits its effect to regulate exocytosis 
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is still controversial. However, it is clear that actin polymerization plays a critical role in this 
process.  
 
Conditional deletion of Rac1 in the uteri leads to severe hemorrhage 
 
Despite a severe reduction of the vascular network on day 8 of pregnancy, we consistently observed 
an increase in blood hemorrhage in Rac1-null decidua, especially around the lateral sinusoids (Figures 
2.6 and 3.7). Using eosin-Y with phloxine to labels red blood cells, we noticed that the cells were 
extravascular, indicative of vascular leakage and hemorrhage (Figure 4.7). Whereas Rac1f/f decidual 
blood was mostly cleared following blood perfusion, Rac1d/d decidua consistently failed to clear, 
indicative of hemorrhage (Figure 4.8). Interestingly, sphingolipid signaling has been shown to prevent 
vascular leakage during uterine angiogenesis [377]. The fact that members of the sphingolipid pathway 
such as Sphk1 are down regulated in the Rac1d/d uteri, suggests that attenuation of sphingolipid 
pathways functioning downstream of RAC1 may be involved in the vascular leakiness observed in 
Rac1d/d uteri (Figure 4.2). In addition to factors in the sphingolipid pathway, tight junction proteins in 
endothelial cells are known to regulate vascular permeability [277]. Interestingly, our microarray 
analysis identified a tight junction molecule such as claudin 3, whose expression was significantly 
downregulated in the absence of uterine Rac1 (Figure 4.2). Claudin 3 (CLDN3) has been shown to be 
present in the blood-brain barrier and loss of Cldn3 in the endothelial cells compromises the integrity 
of the blood-brain barrier [393]. Exactly how stromal RAC1 regulates claudins in the endothelial cells 
remains to be determined, but it is known that decidual cells secrete factors that affect endothelial cell 
function [30, 57, 170, 177, 178, 194, 198, 207]. 
 
It is also possible that the severe hemorrhage observed in Rac1-null uteri is because of the reduction 
in the expression of F13a1 – the gene coding for coagulation factor XIII subtype A1, which is the last 
zymogen to become activated in the blood coagulation cascade and is the factor responsible for 
crosslinking fibrin molecules that stabilize the blood clot. F13a1 global knockout female mice are 
available and are able to get pregnant. However, breeding studies of these mice show that a severe 
uterine hemorrhage develops around day 10 to 12 of pregnancy, which often leads to maternal death 
[384]. Interestingly, there are also loss-of-function mutations in the human isoforms of F13 (A and B 
subunits) [394]. It has been reported that certain women with recurrent miscarriage possess one or both 
of these mutations. The fact that in Rac1d/d mice, there is a significant reduction in this enzyme, 
91 
suggests that RAC1 signaling may be crucial for F13A1 production and/or secretion in the uterus 
during early pregnancy.  
 
 
92 
 
Chapter Figures 
 
 
 
FIGURE 4.1: BIOLOGICAL PROCESS LIST OF GENES THAT WERE DOWN-REGULATED LESS THAN 1.5 FOLD ON MICROARRAY. Gene list shown 
here is a condensed list of genes that were clustered by biological by NIH DAVID. The gene list is based on 576 unique gene probes out of which 
259 gene probes were charted based on their known function within a biological process. The size of the pie slices are representative of the number 
genes within each biological process. Some gene probes are contain within more than one biological process. Not all biological process are listed in 
this pie chart.   
93 
 
 
 
FIGURE 4.2: CONDITIONAL DELETION OF RAC1 IN THE UTERUS LEADS TO DOWN-REGULATION OF SEVERAL GENES THAT ARE CRITICAL FOR 
UTERINE ANGIOGENESIS. Gene expression analysis of day 8 of pregnancy uterine samples confirms the microarray analysis, which showed that 
critical genes involved in uterine vascularization and angiogenesis during pregnancy are critically reduced in Rac1d/d compared to Rac1f/f uteri. Genes 
such as Epas1/Hif2α, Angtp2, and Nrp1 are typically expressed during vascular remodeling in the pregnant uterus. n ≥ 3. Asterisks indicate significant 
differences from controls (* p < 0.05, ** p < 0.01, *** p < 0.001).  
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FIGURE 4.3: EXPRESSION OF TWO WELL-KNOWN GENE TARGETS OF RAC1 ARE UNAFFECTED. Under hypoxic conditions, RAC1 has been shown 
previously to regulate the expression of Hif1α, indirectly leading to an increased production of Vegfa gene expression, via HIF1α. Interestingly, in 
the uterus, conditional deletion of Rac1 does not affect the expression of these two genes on day 8 of pregnancy. n ≥ 3. (p > 0.05). 
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FIGURE 4.4: SUPPRESSION OF THE RAC1 PATHWAY COMPROMISES THE FORMATION OF THE DECIDUAL VASCULAR PLEXUS. (A and B) The 
extent of the angiogenic defect was evaluated using PECAM1/CD31, which is a general marker of endothelial cells and is labeled by the red staining. 
Our results show a dramatic reduction on blood vessel density in Rac1d/d uteri on days of pregnancy 8 (panel A) and 10 (panel B). A diagrammatic 
representation of the vascular network of the implantation nodules is shown to aid in the visualization (adapted and modified with permission form 
[155]). E = embryo, AM = anti-mesometrial decidua, M = mesometrial decidua, LS = lateral blood sinusoids, BZ = basal zone, CS = circular smooth 
muscle zone, CZ = compact zone, DC = decidua capsularis, P = Placenta, L = luminal epithelium, LDZ = lateral decidual zone, MY = myometrium, 
MG = metrial gland, MT = mesometrial triangle. 
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FIGURE 4.4: SUPPRESSION OF THE RAC1 PATHWAY COMPROMISES THE FORMATION OF THE DECIDUAL VASCULAR PLEXUS (CONTINUED). (A 
and B) The extent of the angiogenic defect was evaluated using PECAM1/CD31, which is a general marker of endothelial cells and is labeled by 
the red staining. Our results show a dramatic reduction on blood vessel density in Rac1d/d uteri on days of pregnancy 8 (panel A) and 10 (panel B). 
A diagrammatic representation of the vascular network of the implantation nodules is shown to aid in the visualization (adapted and modified with 
permission form [155]). E = embryo, AM = anti-mesometrial decidua, M = mesometrial decidua, LS = lateral blood sinusoids, BZ = basal zone, CS 
= circular smooth muscle zone, CZ = compact zone, DC = decidua capsularis, P = Placenta, L = luminal epithelium, LDZ = lateral decidual zone, 
MY = myometrium, MG = metrial gland, MT = mesometrial triangle. n ≥ 3.  
 
 
 
 
 
  
97 
 
 
 
 
 
 
 
FIGURE 4.5: CONDITIONAL DELETION OF UTERINE RAC1 IMPAIRS ANGIOGENESIS. Expression of neuropilins in the uterus has been implicated in 
the regulation of angiogenesis. Here, we show that neuropilin 1 (NRP1) expression is dramatically reduced in Rac1d/d decidua on day 8 of pregnancy. 
PECAM1, a marker for endothelial cells, is used to highlight the vascular tree. Lower left inset on the panel shows no primary antibody control. In 
panel B, high magnification images of the vascular plexus (boxed areas 1 and 2) are shown to the right of each image. E = embryo, AM = anti-
mesometrial decidua, M = mesometrial decidua, LS = lateral blood sinuses (also known as vascular web). Bars = 500 µm. n ≥ 3. 
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FIGURE 4.6: CONDITIONAL DELETION OF RAC1 IMPAIRS VEGFA TRANSPORT AND SECRETION OF UTERINE ENDOMETRIAL CELLS. VEGFA 
immunocytochemistry done in decidual cells that were cultured for 72 h in differentiation media are shown here. In all instances, we stained 72 h 
cultured cells, VEGF accumulated in the perinuclear region of the cell, whereas in the control cells VEGF vesicles were either uniformly distributed 
in the cytoplasm or the number was reduced, presumably, due to secretion. Gene expression analysis of the differentiation marker Prl8a2/dPrp, as 
well as Vegfa, shows no change in expression levels between the experimental and control groups. n = 3. Asterisks indicate significant differences 
from controls (*** p < 0.001). 
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FIGURE 4.7: RAC1D/D UTERI DISPLAY EXTRAVASATION OF RED BLOOD CELLS. Extravasation and vascular leakage was confirmed in Rac1d/d mice 
by staining uterine sections on day 8 of pregnancy with eosin-Y containing phloxine. Here, we show that despite a severe reduction in blood 
vasculature in the conditional null uteri, blood hemorrhage, and blood vessel leakiness is observed (inset box). Dotted lines demarcate the blood 
sinuses. Upper left inset on panel shows high magnification images of the boxed area near the lateral sinuses. E = embryo, AM = anti-mesometrial 
decidua, M = mesometrial decidua, LS = lateral blood sinuses (also known as vascular web). Bars = 500 µm. n = 4. 
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FIGURE 4.8: DECIDUA FROM RAC1D/D MICE SHOW SEVERE BLOOD HEMORRHAGE IN THE LATERAL BLOOD SINUSES. Representative images of 
uterine samples following blood perfusion, as compared to a non-perfused Rac1f/f control uterus. The upper images in the panel show three isolated 
implantation nodules, including myometrium. The lower images in the panel show the isolated decidua (rotated 90o from the position observed in 
the upper images of the panel). Here, we show that Rac1-null decidua fail to clear the vascular sinuses, as control decidua does, following vascular 
perfusion with saline containing heparin. All samples shown here were evaluated on day 8 of pregnancy. n = 3. 
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CHAPTER 5: CONCLUSIONS AND WORKING 
MODEL 
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The work presented as part of this dissertation reveals novel roles for RAC1 in the uterus during 
pregnancy (Figure 5.1). Our studies have shown that in uteri lacking RAC1, the embryos are able 
to attach to the epithelium to initiate implantation. However, a six-month breeding study showed 
that female mice with a null mutation of Rac1 in the uterine tissues became severely subfertile, 
and towards the end of the study became sterile. Although we have not unraveled the complete 
repertoire of the pathways affected by this mutation, we were able to identify certain critical events 
in pregnancy that were severely compromised in response to this mutation. For example, we found 
that mutation of uterine Rac1 led to dysregulation of genes that are involved in endometrial stromal 
cell differentiation. Because decidualization involves stromal cell proliferation followed by 
differentiation and RAC1 has been reported previously to regulate proliferation in other systems 
[367], it is of interest to determine the impact of RAC1 ablation on proliferation of stromal cells. 
Our studies revealed no significant difference in cell proliferation of stromal cells in Rac1f/f and 
Rac1d/d uteri. However, a marked upregulation of Alpl and Wnt4 and a downregulation of 
Prl3c1/Plpj gene expression were observed in Rac1-ablated uteri, indicating dysregulated 
differentiation program in Rac1d/d mice during decidualization. The expression of certain other 
genes known to be critical for stromal differentiation such as Bmp2, Gjp1/Cx43, or Vegfa were not 
affected by the deletion of Rac1. It is possible that these genes are functioning independent of 
RAC1 pathway in the uterus. It is also possible that RAC1 regulates the post-transcriptional events 
and is involved in the secretion of some of these factors, including VEGFA. 
A consequence of impaired stromal differentiation in Rac1-null uteri is a defect in uterine 
angiogenesis and blood vessel stability. Gene expression profiling of the decidual tissues showed 
that expression of many genes that are necessary for uterine angiogenesis, such as Hif2α, Anpt2, 
Angpt4, and Nrp1, were significantly downregulated in Rac1-ablated uteri. Interestingly, however, 
Hif1α, a known target of RAC1 during hypoxic conditions [319-322, 324, 395-399], was not 
affected upon uterine deletion of Rac1. It is possible that in decidual uteri, Hif2α rather than Hif1α 
is functioning downstream of the RAC1 pathway to regulate angiogenesis. Consistent with these 
observations, we noted impaired vascular plexus formation in Rac1d/d uteri.  
Immunostaining with PECAM1/CD31 showed a noticeable reduction in the vascular tree in 
Rac1d/d uteri. Absence of blood clearance following perfusion of the blood vasculature clearly 
indicated unstable and leaky blood vessels in uterine tissues of Rac1d/d females. Interestingly, 
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disruption of endothelial cell network, vascular breakage, and hemorrhage during early pregnancy 
has been reported previously in female mice deficient for Sphk1 gene. Consistent with this 
observation, we noted a marked reduction in the expression of Sphk1 in the Rac1d/d uteri. Because 
the suppression of the sphingolipid pathway was sufficient to cause significant alterations in the 
blood vasculature in the Sphk1 mutant mice [377], it is possible that similar events could be 
occurring in the Rac1d/d uteri. Furthermore, we noted with interest that the expression of F13a1, a 
gene involved in clotting and hemorrhage, was reduced in the Rac1d/d uteri, further supporting the 
notion of a compromised vascular tree in these mutant animals.  
Interestingly, the expression of Vegfa was not altered in the uteri of Rac1d/d females. VEGFA, 
acting through VEGF receptors (VEGFR1, VEGFR2, and NRP1) and in conjunction with the 
ANGPT system, coordinates many important processes that ultimately lead to vascular remodeling 
[178, 184, 390, 400]. Gene expression analysis on day 8 of pregnancy showed a marked reduction 
in the expression of Angpt2 and Nrp1 in the uterine tissue. Both ANGPT2 and NRP1 have been 
implicated in uterine angiogenesis [30, 57, 72, 178, 195, 198, 400, 401]. The fact that these two 
molecules are downregulated in the Rac1d/d uteri further supports the angiogenic defect observed 
in these animals. Additionally, VEGF, in the absence of the ANGPT system can lead to abnormal 
vascular leakage and blood vessel instability [184]. It should be noted, however, that we made one 
critical observation with regard to VEGFA secretion in Rac1-deficient decidual cells. These cells 
displayed a marked reduction in VEGFA secretion compared to Rac1-intact stromal cells. 
However, besides decidual cells, trophoblasts [57, 62, 69, 186, 402] and uterine natural killer cells 
[360, 403, 404] can also contribute to the production and secretion of VEGFA, which can lead to 
dysregulated VEGFA signaling. Taken together, we are of the view that severe vascularization 
defect observed in the Rac1d/d female mice is the primary cause of embryo loss by mid-gestation.  
It has been recognized for a long time that the differentiated decidual cells secrete a variety of 
factors that are important for the growth and development of the implanted embryo [23-25, 29, 91, 
121-123]. However, the molecular mechanisms by which the decidual cells undergo secretory 
activity remain largely unknown. In this study, we show for the first time that primary decidual 
cells from Rac1d/d uteri display reduced VEGFA secretion, despite no impairment in VEGFA 
synthesis and initial packaging into secretory vesicles. It is possible that decidual cells utilize 
RAC1-dependent actin polymerization for vesicle transport. CDC42, like RAC1, can induce actin 
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polymerization and has been involved in vesicle secretion. However, CDC42 is known to regulate 
the earlier events of vesicle trafficking (i.e. rER to Golgi), whereas RAC1 seems to regulate the 
later stages of trafficking (i.e. Golgi to plasma membrane) [310]. Nonetheless, it is clear that a 
RAC1-dependent secretory function of decidual cells is important for embryo survival and 
maintenance of pregnancy. 
Studies aiming to understand the underlying reasons for failures in implantation and placental 
development are clinically important. Indeed, about one-third of normal human pregnancies end 
in spontaneous abortion, and a fair percentage of these pregnancies will be lost before they are 
detected clinically [12-14]. Similarly, failure in embryonic development, due to defects in the 
embryo or the maternal environment, account for almost 80% of the embryonic loss that occurs in 
farm animal species [405-407]. In humans, abnormalities in the vascular connections result in 
preeclampsia and/or IUGR, diseases that account for significant morbidity and mortality to both 
the mother and fetus [12, 44, 51, 59, 62]. Therefore, research aimed to understand the physiological 
and pathological events that lead to pregnancy complications are required to further our 
understanding of this complicated process. Studies described in this thesis suggest that 
disturbances in RAC1-dependent pathways may be relevant to humans with recurrent pregnancy 
failures. 
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Chapter Figure 
 
FIGURE 5.1: WORKING MODEL FOR THE ROLE OF RAC1 IN THE UTERUS DURING EARLY EVENTS OF PREGNANCY. Activation of RAC1 in the 
endometrium during early events of pregnancy results in a series of signaling cascades that ultimately: 1) regulate gene expression of factors 
responsible for stromal cell differentiation, as well as angiogenesis and vascular stability; 2) induce changes in actin dynamics to promote vesicle 
transport from the rough endoplasmic reticulum (rER) to the plasma membrane, as well as the secretion of the protein content to the extracellular 
matrix. Finally changes in actin dynamics also promote 3) cell migration to establish an intimate relationship with the embryo. All these events are 
necessary to ensure embryo survival and pregnancy maintenance.  
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CHAPTER 6: FUTURE DIRECTIONS 
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The work described in this dissertation uncovered new roles for RAC1 in uterine tissue and raised 
interesting questions related to maternal-fetal interactions during pregnancy. RAC1, a pleotropic 
signaling molecule, is known to be involved in various biological processes. We have observed 
some of the critical functions displayed by RAC1 in the uterus during early pregnancy.  
 
During the exploration of the Rac1d/d mouse model, we made a few critical observations that might 
be of clinical importance. We noted that implanted embryos displayed a dysregulated trophoblast 
expansion by day 8 of pregnancy (Appendix C, Figure C3.1). Although we do not know what 
drives trophoblast cells to over expand in the uterus of the conditional null mice, it is our hypothesis 
that the overexpansion of the trophoblast cells is most likely linked to the inherent impairment of 
Rac1-deficent stromal cells. Our preliminary wound-healing assay (data not shown) showed that 
Rac1-deficient stromal cells exhibit migratory impairments. Furthermore, our studies have 
revealed that the Rac1-null decidual cells have an overall secretion defect. Therefore, it is possible 
to assume that the dysregulated trophoblast expansion could be the result of a combinatorial effect 
arising from maternal deficiencies in migration and secretion.  
 
In an attempt to gain insights into the potential pathways that might be dysregulated in the decidua, 
we performed gene expression analysis of known molecules that have been implicated in 
regulating trophoblast migration (Appendix C, Figure C3.2). Whereas IGF2 is secreted from the 
blastocyst to promote trophoblast migration, IGFBPs, secreted from the decidual cells, are thought 
to interfere with this process. Our preliminary data show an upregulated expression of Igbp4, while 
gene expression of adrenomedullin (Adm) and Igfbp3 is not changed. Both Igfbp4 and Adm have 
been suggested to regulate trophoblast migration. In particular, high expression of IGBP4 has been 
found in women with recurrent miscarriage. Because decidual cells deficient for RAC1 exhibit a 
defect in secretory activity, it is possible that certain factors critical for proper functioning of the 
mother and the fetus are absent in Rac1-null uteri. Thus, it would be important to determine if 
other factors besides VEGFA exhibit impaired secretory activity. It is clear that the secretory 
functions of the decidual cells are crucial to maintain the embryo under control in the proper 
cellular compartment. Any perturbation in this process and a dysregulation in the migratory 
potential of the trophoblast cells can have serious consequences to the outcome of pregnancy. 
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Thus, elucidating how decidual cells precisely regulate trophoblast invasion has great clinical 
significance.   
 
Intrauterine fetal growth restriction (IUGR) is another area of great clinical importance. It is now 
widely accepted that the exposure of developing embryo to the environment can have severe 
consequences on the metabolic phenotype of an organism without alterations in the genomic 
sequence. Epigenetic modifications caused by the nutritional environment of the developing 
embryo have gained great interest recently because of the obesity epidemic that is affecting the 
USA. Interestingly, our preliminary observations of implantation nodules obtained on day 15 of 
pregnancy, suggest that the Rac1-deficient uterine environment may not be fully conducive to 
proper embryonic growth. When implantation nodules were dissected, we noticed growth 
retardation in the embryos we were able to collect (Appendix C, Figure C3.3B). Although we have 
a small sample size, we did notice a strong trend towards IUGR, as assessed by the weight of the 
embryos from Rac1f/f and Rac1d/d mice. Additionally, the placentas obtained from these growth-
retarded embryos displayed abnormal shapes, and were significantly heavier than the control 
placenta (Appendix C, Figures C3.3B to C3.3D). Consistent with the phenotype associated with 
IUGR, implantation nodules collected on day 12 of pregnancy displayed abnormalities in blood 
vasculature. Further, uterine samples from Rac1d/d mice showed intermediate to no modifications 
of spiral artery, which is detrimental to maintenance of pregnancy (Appendix C, Figure C3.4). 
Further studies should establish whether the lack of spiral artery modification combined with the 
vascular defect is driving embryonic loss at mid-gestation in the Rac1d/d mouse. We anticipate that 
further studies in each of these areas will provide an in depth knowledge of function of RAC1 in 
the uterus at distinct stages of early pregnancy. Ultimately this knowledge will be useful in 
developing treatment options for women with pathologies associated with pregnancy, including 
recurrent miscarriage and IUGR.   
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APPENDIX A: BREEDING STRATEGIES FOR THE FOUNDER AND EXPERIMENTAL 
COLONY 
 
 
 
FIGURE A.1: BREEDING STRATEGY FOR GENERATING THE RAC BREEDING COLONY. Transgenic mice 
carrying the PgrCre knockin mutation were generously provided by Drs. Franco De Mayo and John Lyndon, 
Baylor College of Medicine, TX. Mice carrying the knockin floxed mutation for Rac1 gene were generously 
provided by Dr. Ann Sutherland, University of Georgia, GA. To establish the breeding colony, animals 
from F1 were bred to each other. Only a select group of animals from the resulting F2 progeny (shown in 
the figure above) were used to generate the experimental animal. 
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FIGURE A.2: EXPECTANCY FREQUENCIES OF ANIMALS/GENOTYPE BASED ON THE BREEDING 
STRATEGY FOR GENERATING THE FOUNDING ANIMAL COLONY. The table shows the expected frequency 
of animals in the F2 progeny, by genotype and sex, resulting from the mating of F1 male with F1 female.  
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FIGURE A.3: BREEDING STRATEGY FOR GENERATING THE EXPERIMENTAL ANIMALS. The experimental 
animals for the project animals were obtained by mating mice from the F2 progeny using the scheme above. 
The tables on the next page show the expected frequency of animals, by genotype and sex, resulting from 
any F2 breeding combinations. 
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FIGURE A.4: EXPECTANCY FREQUENCIES OF ANIMALS/GENOTYPE BASED ON THE BREEDING 
STRATEGY FOR GENERATING THE BREEDING COLONY. The table shows the expected frequency of 
experimental animals, by genotype and sex, resulting from the mating of F2 male with F2 female.  
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Fertility Studies 
 
 
 
FIGURE A.5: BREEDING STRATEGY FOR THE SIX-MONTH BREEDING STUDY. To rule out the possibility 
that the subfertility in Rac1d/d mice is due to an inherent defect in the embryo, we bred the Rac1d/d and 
Rac1f/f females to wild-type male mice of proven fertility. This breeding scheme generated pups that were 
heterozygous for Rac1 gene. Therefore, any problems associated with pregnancy are likely due to a defect 
in the maternal decidua, and not in the embryo or its membranes. 
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FIGURE A.6: EXPECTANCY FREQUENCIES OF ANIMALS/GENOTYPE BASED ON THE SIX-MONTH 
BREEDING STUDY. Fertility testing was done using the breeding scheme above. The tables show the 
expected frequency of animals, by genotype and sex, resulting from the breeding combinations. 
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APPENDIX B: GENE EXPRESSION VALIDATION OF OTHERS MOLECULES INVOLVED IN STROMAL CELL 
DECIDUALIZATION AND ANGIOGENESIS 
 
 
FIGURE B.1: GENE EXPRESSION OF OTHER CRITICAL MOLECULES, IMPLICATED IN STROMAL CELL DIFFERENTIATION, WERE NOT AFFECTED 
BY THE CONDITIONAL RAC1 MUTATION. 
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FIGURE B.2: GENE EXPRESSION OF OTHER MOLECULES IMPLICATED IN UTERINE ANGIOGENESIS. 
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APPENDIX C: PRELIMINARY DATA FOR FUTURE DIRECTIONS 
 
C1. Background information and the rationale 
 
Embryo implantation into the maternal endometrium is crucial for embryo survival, and therefore 
sustains pregnancy. It well establish that the invading embryo promotes well-orchestrated vascular 
remodeling in the uterus to provide access to nutrient-rich maternal blood. Decidual cells are 
known to actively regulate this process through complex crosstalk between the embryonic and 
maternal tissues. In some pathological conditions associated with pregnancy, this crosstalk is 
disrupted. In cases of shallow invasion of the trophoblast into the endometrium, the fetal stress 
that arises causes hypertensive crisis condition in the mother, known as preeclampsia. In the US 
alone, about 5% of pregnancies will develop preeclampsia and, so far, the only effective solution 
is to deliver the baby, which often is premature. In contrast, in about 5% of pregnancies, 
trophoblasts will migrate beyond their limits and placenta accreta will occur. In 70% of patients 
with placenta accreta, trophoblast cells will only invade past the functionalis decidual layer (where 
the trophoblast usually stops) into the basalis decidua. However, in more severe cases, placenta 
increta or placenta percreta occurs, resulting in excessive invasion of the trophoblast deep into the 
myometrium or into the peritoneum, respectively. In either case, surgical removal of the placenta 
is necessary, which can put the mother and baby at risk. In both the instances, under- or over-
nutrition of the fetus can have long lasting effects on the conceptus’ metabolomics that can be 
exacerbated into metabolic disturbances later in adulthood, like early onset diabetes, obesity, or 
any other metabolic-related disease. 
 
Early in vitro studies have suggested that RAC1 is present in the decidual cells and seems to play 
a role in embryo invasion and placentation. However, our work has clearly showed that RAC1 
activity is not necessary for embryo attachment and implantation into the endometrium (Chapter 
3). However, uterine deletion of the Rac1 gene led to an apparent overgrowth of the trophoblasts 
in the uterus of Rac1d/d females on day 8 of pregnancy (Figures 3.6 and C3.1). Therefore, we 
decided to begin exploring how conditional deletion of Rac1 in the uterine tissues leads to 
overgrowth of the trophoblast, and whether this overexpansion of the trophoblast leads to placental 
abnormalities during mid-gestation. Because mice with conditional mutation for RAC1 have 
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severe angiogenic defects (Chapter 4), we only focused on those implantation nodules that were 
as morphologically similar as possible to the control implantation nodules. 
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C2. Materials and Methods 
 
Animals and Tissue Collection 
 
All animal breeding, housing, procedures, experiments, and euthanasia were approved and 
conducted according to the guidelines of the Institutional Animal Care and Use Committee of 
University of Illinois at Urbana-Champaign. The health and care of the animals were provided by 
the veterinarians and staff of Division of Animal Resources. Rac1 conditional null mice were 
generated using Cre-LoxP strategy [347] (Figure 3.1A). Mice expressing homozygous copies of 
the Rac1 gene flanked by loxP sites [Pgr+/+ Rac1f/f (official gene symbol Rac1tm1Djk/J), or Rac1f/f 
from now onwards] [267] were obtained from Dr. Ann Sutherland (University of Georgia) in a 
C57BL/6-129SV background. Mice carrying the Cre Recombinase under the control of the 
progesterone receptor (Pgr) promoter [348] [PgrCre/+ Rac1+/+ (official gene symbol Pgrtm2(cre)Lyd/+), 
or PgrCre from now onward], were obtained from Drs. John Lyndon and Francesco De Mayo 
(Baylor College of Medicine) in a C57BL/6 background. To establish the mouse colony for this 
study, initial breeding between the two mouse lines was done to obtain the F1 progeny, which are 
heterozygous for Pgr and Rac1 (Appendix A). Female mice used for this study were generated by 
breeding male mice of specific genotypes from the F2 progeny (see Figure 3.1B) with Rac1f/f 
female mice. Genotyping of the animals was performed following the protocols established by the 
respective laboratories that generated the transgenic mice [267, 348] (Appendix A). Conditional 
knockout female mice (PgrCre/+ Rac1f/f) will be referred to as Rac1d/d from now onwards. 
 
Rac1f/f or Rac1d/d females were euthanized by CO2 asphyxiation, followed by a blood draw via 
cardiac puncture, and cervical dislocation. Uteri from pregnant mice were collected at different 
time points during pregnancy. The harvested organs were either fixed for histological evaluation 
[immersion-fixed in 10% neutral-buffered formalin (NBF)], flash frozen in liquid N2 for RNA or 
frozen sectioning. For samples collected at different time points during pregnancy, identification 
of a copulatory plug following mating was used as a reference and for our experimental purposes, 
to indicate day 1 of pregnancy. 
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Some of the implantation nodules collected during pregnancy were used for morphological 
evaluation of the decidua or placenta. The decidual mass was exposed by mechanical removal of 
the myometrium. Pictures were taken using a Leica M165 FC dissection scope connected to a 
Leica 450 C camera with c-mount interface containing a 5 Megapixel CCD sensor. Similarly, for 
morphological evaluation of embryos on day 15 of pregnancy, mechanical removal of the 
myometrium was done under the dissecting scope, as mentioned above. At least two implantation 
nodules/female were analyzed on day 15 of pregnancy. 
 
Quantitative real-time PCR and RNA Isolation 
 
Total RNA was isolated from tissues or cells using TRIzol reagent (Invitrogen) followed by RNA 
cleanup kit (Qiagen), according to the manufacturer’s instructions. RNA was converted to cDNA 
using a kit (Applied Biosystems), according to the manufacturer’s instructions. Oligonucleotides 
specific for genes of interest were developed (see Appendix F for details) and qPCR reactions were 
carried out using SYBR-green master mix (Applied Biosystems) on a 7500 Applied Biosystems 
real-time PCR machine (Applied Biosystems). Gene expression data analysis were done using the 
2-ΔΔCt method [357] and 36b4 gene – which is conserved among many species and encodes an 
acidic ribosomal phosphoprotein P0 that interacts with 40S ribosomal subunit – was used as a 
housekeeping gene and loading control [358].  
 
Immunohistochemistry, Immunocytochemistry, and Immunofluorescence  
 
Cultured cells or paraffin-embedded uterine sections were subjected to immunohistochemistry or 
immunocytochemistry as described previously [32, 353, 355, 356]. Briefly, paraffin-embedded 
sections were deparaffinized in xylene and rehydrated in a series of graded alcohols followed by 
rinsing in tap water. When frozen tissue were used, the sections were thawed at room temperature 
for 5 min, then fixed for another 5 min in 10% NBF. When cells were used, they were fixed for 
another 5 min in 10% NBF. Sections or cells then were rinsed in 1x phosphate-buffer saline (PBS), 
followed by serum blocking using 10% non-immunized serum for 1 h at room temperature. 
Following serum block, slides were incubated with a solution containing the diluted antibody (see 
Appendix E for details) and 1% serum in 1x PBS overnight at 4 oC in a humidified chamber (for 
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slides) or in the culture plates (for cells). Following overnight incubation, slides were washed 3x 
5 min with 1x PBS, then incubated with diluted fluorescent-labeled secondary antibody (see 
Appendix E for details) for 1 h at room temperature. Samples then were rinsed in 1x PBS and 
mounted with a medium containing DAPI. Pictures were taken using the Olympus BX51 
microscope equipped for light and fluorescent imaging and was connected to a Jenoptik ProgRes 
C14 digital camera with c-mount interface containing a 1.4 Megapixel CCD sensor. Fluorescent 
images were merged and processed using CS4 Adobe Photoshop Extend (Adobe Systems). 
 
Embryo and placental perimeter measurement 
 
Java-based image analysis software NIH ImageJ (http://rsb.info.nih.gov/nih-image/) was utilized 
for the outlining and making measurements in embryonic tissues. The perimeter of embryos on 
day 8 of pregnancy, which were previously stained with hematoxylin and eosin, and the placenta 
on day 15 of pregnancy were also measured using this software.  
 
Statistical analysis 
 
Experimental data were collected from a minimum of three independent animals (not from the 
same litter), which were subjected to the same experimental conditions. Embryo weights and qPCR 
results are expressed as LSMeans and mean ± S.E.M, respectively. Statistical analysis was done 
using Student’s t-test. An analysis of equal variances was done on all numerical data to determine 
whether a parametric or non-parametric hypothesis test was appropriate. Data were considered 
statistically significant if p ≤ 0.05, and is indicated by an asterisks in the figures. All data were 
analyzed and plotted using GraphPad Prism 4.0 (GraphPad Software) or Microsoft Excel 2013 
(Microsoft Corporation). 
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C3. Preliminary data 
 
 
 
 
FIGURE C3.1: CONDITIONAL DELETION OF RAC1 IN UTERINE DECIDUAL CELLS, DOES NOT PREVENT EMBRYO IMPLANTATION, BUT LEADS TO 
TROPHOBLAST OVERGROWTH IN VIVO. (A) Implantation nodules collected on day 8 of pregnancy were serially sectioned and every 10th section 
was stained with hematoxylin and eosin. The section with the maximum embryo size was used to measure the total perimeter covered by the 
trophoblast (outlined by the dotted lines). The data show a close trend toward trophoblast outgrowth (p = 0.08). 
 
 
  
149 
 
 
 
 
 
 
 
FIGURE C3.1: CONDITIONAL DELETION OF RAC1 IN UTERINE DECIDUAL CELLS, DOES NOT PREVENT EMBRYO IMPLANTATION, BUT LEADS TO 
TROPHOBLAST OVERGROWTH IN VIVO (CONTINUED). (B) Isolated embryos on day 8 of pregnancy, showed outgrowth of the trophoblast cells. 
Bars = 1 mm. n ≥ 5. 
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FIGURE C3.2: GENE EXPRESSION PROFILE OF REGULATORS OF TROPHOBLAST EXPANSION. IGFBPs are known to interfere with embryo-
produced IGF2, which promotes forward migration of trophoblast cells into the maternal endometrium. Of the known IFGBPs that could be found 
in the mouse uterus, IGFBP4 is only expressed by the uterine decidua [90, 92], while IGFBP3 can be expressed by both the decidua and the 
myometrium. Adrenomedullin has been shown to be secreted by both the maternal tissues, as well as the embryonic tissues. Our data show that on 
day 8 of pregnancy, only IGFBP4 is differentially regulated by the conditional deletion of RAC1 in the uterus. n = 4. Asterisks indicate significant 
differences from controls (** p < 0.01). 
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FIGURE C3.3: CONDITIONAL DELETION OF RAC1 IN UTERINE TISSUES LEADS TO PLACENTAL ABNORMALITIES AND INDICATIONS OF 
INTRAUTERINE GROWTH RESTRICTION. (A and B) Samples collected on day 15 of pregnancy show a wide range of variation on the placental and 
embryo outcome. However, consistently all the implantation nodules that were dissected from Rac1d/d females showed placental shape abnormalities 
and wide-range in the level of hemorrhage that was observed in the placental tissues.  
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FIGURE C3.3: CONDITIONAL DELETION OF RAC1 IN UTERINE TISSUES LEADS TO PLACENTAL ABNORMALITIES AND INDICATIONS OF 
INTRAUTERINE GROWTH RESTRICTION (CONTINUED). (C) Furthermore, some of the placentas had adopted a convex shape in the embryo side 
of the placenta, instead of the normal concave shape. (D) Although these placentas did not extend inwards towards the uterus, the placentas obtained 
from Rac1d/d females were expanded sideways and displayed abnormal shapes, as indicated by the increased placental perimeter. Similarly, these 
placentas were significantly heavier than control counterparts, suggesting placental modifications, perhaps, as a result of uterine RAC1 mutation or 
an adaptation to the hemorrhagic environment, which led to growth restrictions as observed in some of the more severe embryos. Bars = 1 cm. n = 
3. Asterisks indicate significant differences from controls (* p < 0.05, ** p < 0.01). 
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FIGURE C3.4: CONDITIONAL DELETION OF RAC1 IN UTERINE TISSUES LEADS TO PLACENTAL ABNORMALITIES THAT DISPLAY IMPAIRED 
VASCULAR REMODELING. (A) This section show the expected placental structures on day 12 of pregnancy. Bars: low power images = 500 µm and 
high power images = 200 µm. White circles highlight blood vessels in the decidua. E = embryo, P = placenta, and M = mesometrial decidua. Area 
1 = placenta (Red = CYTOKERATIN 8 positive cells); Area 2 = feto-maternal interphase; Area 3 = deep decidua and myometrium. All sections 
shown here were stained with alpha smooth muscle actin (αSMA = green fluorescent stain) to assess the extent of vascular remodeling. 
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FIGURE C3.4: CONDITIONAL DELETION OF RAC1 IN UTERINE TISSUES LEADS TO PLACENTAL ABNORMALITIES THAT DISPLAY IMPAIRED 
VASCULAR REMODELING (CONTINUED). (B and C) Samples collected on day 12 of pregnancy show a wide range of variation on the placental 
outcome as shown here these implantation nodules from Rac1d/d females. Whereas one of the samples displays a placenta with normal histological 
features as those seen in the controls (panel B), the lower most panel shows a disorganized, bifurcated (panel C, below), placenta (red fluorescent 
stain = CYTOKERATIN 8). All sections shown here were stained with alpha smooth muscle actin (αSMA = green fluorescent stain) to assess the 
extent of vascular remodeling. Our results show, that although there is some degree of vascular remodeling that can occur in Rac1d/d uteri, this seems 
to be partial as there were some areas in the decidua that stained positive for αSMA, which were not positive in the control samples (areas 2 and 3). 
Furthermore, it seems that in the severe cases, little vascular remodeling occurs, and whether this is a consequence of improper decidual function or 
the fact that the embryo might be dying, remains to be elucidated. Bars: low power images = 500 µm and high power images = 200 µm. White 
circles highlight blood vessels in the decidua. E = embryo, P = placenta, and M = mesometrial decidua. Area 1 = placenta (Red = CYTOKERATIN 
8 positive cells); Area 2 = feto-maternal interphase; Area 3 = deep decidua and myometrium. 
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FIGURE C3.4: CONDITIONAL DELETION OF RAC1 IN UTERINE TISSUES LEADS TO PLACENTAL ABNORMALITIES THAT DISPLAY IMPAIRED 
VASCULAR REMODELING (CONTINUED). (B and C) Samples collected on day 12 of pregnancy show a wide range of variation on the placental 
outcome as shown here these implantation nodules from Rac1d/d females. Whereas one of the samples displays a placenta with normal histological 
features as those seen in the controls (panel B), the lower most panel shows a disorganized, bifurcated (panel C), placenta (red fluorescent stain = 
CYTOKERATIN 8). All sections shown here were stained with alpha smooth muscle actin (αSMA = green fluorescent stain) to assess the extent of 
vascular remodeling. Our results show, that although there is some degree of vascular remodeling that can occur in Rac1d/d uteri, this seems to be 
partial as there were some areas in the decidua that stained positive for αSMA, which were not positive in the control samples (areas 2 and 3). 
Furthermore, it seems that in the severe cases, little vascular remodeling occurs, and whether this is a consequence of improper decidual function or 
the fact that the embryo might be dying, remains to be elucidated. Bars: low power images = 500 µm and high power images = 200 µm. White 
circles highlight blood vessels in the decidua. E = embryo, P = placenta, and M = mesometrial decidua. Area 1 = placenta (Red = CYTOKERATIN 
8 positive cells); Area 2 = feto-maternal interphase; Area 3 = deep decidua and myometrium. n = 3 
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APPENDIX D: GENOTYPING PRIMERS AND PROTOCOL 
 
PCR Cycling conditions for genotyping  
 
Rac1 Genotyping 
 
Rac1 Primers: 
P91: 5'-GAT GCT TCT AGG GGT GAG CC-3' 
P45: 5'-CAG AGC TCG AAT CCA GAA ACT AGT A-3' 
P33: 5'-TCC AAT CTG TGC TGC CCA TC-3'  
 
Cycling Program for Rac1: 
1. 9 minutes @ 92 °C 
2. 30 sec @ 92 °C 
3. 30 sec @ 65 °C 
4. 1 minute @ 72 °C 
5. Cycle 35 times steps 2 to 4 
6. 3 minutes @ 72 °C 
7. ∞ @ 4 oC 
8. End 
 
This reaction condition gives 3 potential bands: 
 
Rac1 Wild-type band 115 bp 
Rac1 knockout band  140 bp 
Rac1 floxed band 242 bp 
 
Run in 2-3% Agarose Gel in TBE Buffer for at least 45 minutes @ 120 Vconstant 
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PgrCre Genotyping 
 
PgrCre Primers: 
R1: 5'-TAT ACC GAT CTC CCT GGA CG-3' 
F1: 5'-ATG TTT AGC TGG CCC AAA TG-3' 
F2: 5'-CCC AAA GAG ACA CCA GGA AG-3' 
 
Cycling Program for PgrCre: 
1. 5 minutes @ 94 °C 
2. 1 minute @ 94 °C 
3. 1 minute @ 60 °C 
4. 2 minute @ 72 °C 
5. Cycle 39 times steps 2 to 4 
6. 7 minutes @ 72 °C 
7. ∞ @ 4 oC 
8. End 
 
This reaction condition gives 2 bands: 
 
Pgr Wild-type band 250 bp 
PgrCre band   600 bp 
 
Run in 1.5-2% Agarose Gel in TBE Buffer for at least 30 minutes @ 120 Vconstant 
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APPENDIX E: ANTIBODY DILUTIONS 
 
Immunohistochemistry  
 
For immunostaining, the blocking serum (donkey or goat) used depended on the secondary  
 
Primary antibodies 
Antibody Dilution used Company Catalog Host Species 
Anti-Human MKI67 1:750 BD Parmigen 550609 Mouse 
Anti-Mouse 
PRL8A2/dPRP 
1:750  Serum obtained 
from Dr. Soares 
----- Rabbit 
Anti-Mouse PECAM1/ 
CD31 
1:200 BD Parmigen 557355 Rat 
Anti-Mouse α-SMA 1:200 Abcam Ab5694 Rabbit 
Anti-Mouse Pan VEGFA 
(A-20) 
1:100 Santa Cruz 
Biotechnology 
SC-152 Rabbit 
Anti-Mouse 
CYTOKERATIN 8  
(Troma-I) 
1:50 Hybridoma Bank ----- Rat 
Anti-Mouse NRP1 
(EPR3113) 
1:200 Abcam Ab81321 Rabbit 
 
Secondary antibodies 
Biotinylated Anti-Rabbit 
IgG 
1:250 Invitrogen 95-6543B Goat 
Biotinylated Anti-Mouse 
IgG 
1:250 Invitrogen 95-6143B Goat 
Cy3-Conjugated Anti-Rat 
IgG 
1:250 Jackson 
ImmunoResearch 
712-165-
150 
Donkey 
Cy3-Conjugated Anti-
Rabbit IgG 
1:250 Jackson 
ImmunoResearch 
711-165-
152 
Donkey 
Alexa 488-Conjugated 
Anti-Mouse IgG 
1:250 Jackson 
ImmunoResearch 
715-545-
151 
Donkey 
 
Fluorophores 
Texas Red Avidin 1:500 Vector A-2006 ----- 
Fluorescein Avidin 1:500 Vector A-2001 ----- 
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Western Blots 
 
Antibody Dilution used Company Catalog Host Species 
Anti-Mouse RAC1 
(0.T.127) 
1:1000 Abcam Ab33186 Mouse 
Anti-β-Tubulin 1:2000 Sigma T5293 Mouse 
HRP-Conjugated Anti-
Mouse IgG 
1:5000 Sigma A9044 Rabbit 
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APPENDIX F: PRIMER SEQUENCES FOR GENE EXPRESSION ASSAYS 
 
The primers for gene expression assays were generated using the Custom Primers - OligoPerfect™ 
Designer software (Invitrogen), based on the known mRNA sequence of the genes of interest. The 
obtained oligonucleotide sequence were then submitted to NCBI BLAST tool to confirm their 
specificity to the gene of interest. Sequences with 100% max match identity were used for gene 
expression analysis. For all the primer sequences below, a single dissociation curve was obtained 
during qPCR analysis. 
 
 
Parameters used with the Invitrogen software: 
 Primer size 18 – 27 (min – max) ok, with opt (optimal) 20 
 Primer temp 57 – 63, with 60 opt 
 % GC 45 – 55, 50 opt 
 Product size 100 – 150 bp 
 Salt and primer concentration 50 nM 
 The 3’ nucleotide must be a perfect match to the target cDNA sequence 
 
 
List of primers 
 Primers were purchased from either Sigma or Invitrogen.  
 
36b4 Primers: 
F: 5’-CATCACCACGAAAATCTCCA-3’ 
R: 5’-TTGTCAAACACCTGCTGGAT-3’ 
Rac1 Primers: 
F: 5’-CTGAAGTGCGACACCACTGT-3’ 
R: 5’-CTTGAGTCCTCGCTGTGTGA-3’ 
Rac2 Primers: 
F: 5’-CAATGCAGGCCATCAAGTGT-3’ 
R: 5’-TGGGGATGTATTCTCCAGGG-3’ 
Rac3 Primers: 
F: 5’-ATCAAGTGCGTGGTGGTTG-3’ 
R: 5’-CGTTGGCTGAGTAGTTGTCG-3’ 
Cdc42 Primers: 
F: 5’-TGCTGCTATGAACGCATCTC-3’ 
R: 5’-CATGAGTGCATGTGGGTAGG-3’ 
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RhoA Primers: 
F: 5’-TGGTGATGGAGCTTGTGGTA-3’ 
R: 5’-TCTACCTGCTTCCCATCCAC-3’ 
Hif1α Primers: 
F: 5’-TCTCCAAGCCCTCCAAGTATG-3’ 
R: 5’-CTACAGTGGTGGCAGTTGTG-3’ 
Epas1/Hif2α Primers: 
F: 5’-CAGGCAGTATGCCTGGCTAATTCCAGTT-3’ 
R: 5’-CTTCTTCCATCATCTGGGATCTGGGACT-3’ 
Cldn3 Primers: 
F: 5’-CCACTACCAGCAGTCGATGA-3’ 
R: 5’-AGCCTGTCTGTCCTCTTCCA-3’ 
F13a1 Primers: 
F: 5’-CAAGGATTCGGTGTGGAACT-3’ 
R: 5’-GCTTAACGGCTTGGACAGAG-3’ 
Wnt4 Primers: 
F: 5’-TTCTCACAGTCCTTTGTGGACG-3’ 
R: 5’-TCTGTATGTGGCTTGAACTGTG-3’ 
Wnt5a Primers: 
F: 5’-TCTTGGTGGTCTCTAGGTATG-3’ 
R: 5’-CACTGTGCTGCAGTTCCATCT-3’ 
Alpl Primers: 
F: 5’-TGGATGTGACCTCATTGC-3’ 
R: 5’-CATATAACACCAACGCTCAG-3’ 
Gpj1/Cx43 Primers: 
F: 5’- CTATCGTGGATCAGCGACCTTC-3’ 
R: 5’- CACGGGAACGAAATGAACACC-3’ 
Prl8a2/dPRP Primers: 
F: 5’-CTCACTTCTCAGGGGCACTC-3’ 
R: 5’-GGATCTGAGCAGCCATTCTC-3’ 
Runx1 Primers: 
F: 5’-AGATTCAACGACCTCAGGTTT-3’ 
R: 5’-CGGATTTGTAAAGACGGTGA-3’ 
Pgr Primers: 
F: 5’-CTAAATGAGCAGAGGATGAAGGAG-3’ 
R: 5’-TGGGCAACTGGGCAGCAATAAC-3’ 
Vegfa Primers: 
F: 5’-CAGGCTGCTGTAACGATGAA-3’ 
R: 5’-TTTCTTGCGCTTTCGTTTTT-3’ 
Tek/Tie2 Primers: 
F: 5’-TCCGAGCTAGAGTCAACACC-3’ 
R: 5’-GCCATCCACTATTGTCCAAG-3’ 
Vegfr1/Flt1 Primers: 
F: 5’-TGGCCAGAGGCATGGAGT-3’ 
R: 5’-TCGCAAATCTTCACCACATTG-3’ 
Vegfr2/Flk1 Primers: 
F: 5’-TCTGTGGTTCTGGTGGAGA-3’ 
R: 5’-GTATCATTTCCAACCACCCT-3’ 
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Pecam1/Cd31 Primers: 
F: 5’-GAGGCCCAATCACGTTTCAGTT-3’ 
R: 5’-TCCTTCCTGCTTCTTGCTAGCT-3’ 
Angpt1 Primers: 
F: 5’-GGGGCTGGAAGGAGTATAAA-3’ 
R: 5’-CCTCAGCATGTACTGCCTCT-3’ 
Angpt2 Primers: 
F: 5’-TCCAAGAGCTCGGTTGCTAT-3’ 
R: 5’-AGTTGGGGAAGGTCAGTGTG-3’ 
Angpt4 Primers: 
F: 5’-AGCAGCCAACTGACGGAGTTT-3’ 
R: 5’-CTCTGCACAGTCCTGGAACA-3’ 
Sphk1 Primers: 
F: 5’-CATGCATGAGGTGGTGATG-3’ 
R: 5’-TGCTCGGTACCCAGCATAGTG-3’ 
Nrp1 Primers: 
F: 5’-TGTGGGTACACTGAGGGTCA-3’ 
R: 5’-CAGCAATTCCACCAAGGTTT-3’ 
Mmp9 Primers: 
F: 5’-TCTTCCCCTTCGTCTTCCT-3’ 
R: 5’-TATACAGCGGGTACATGAGCG-3’ 
Adm Primers: 
F: 5’-GGGTTCACTCGCTTTCCTAGGGTTCACTCGCTTTTCTA-3’ 
R: 5’-GCTGCTGGATGCTTGTAGTTGCTGGCTGGATGCTTGTAGTT-3’ 
Igf2 Primers: 
F: 5’-ATGACACCTGGAGACAGTCC-3’ 
R: 5’-TGGCCTCTCTGAACTCTTTG-3’ 
Igfbp3 Primers: 
F: 5’-GGTCCTTATTGTTGCCATCTC-3’ 
R: 5’-AGATGCCTGACAAAGAAAGG-3’ 
Igfbp4 Primers: 
F: 5’-TGCAGACCTCTGACAAGGAT-3’ 
R: 5’-GTCCCCACGATCTTCATCCTT-3’ 
Prl3c1/Plpj Primers: 
F: 5’-GTTTTTGATTTTGCCATGCT-3’ 
R: 5’-TCGCAAATCTTCACCACATTG-3’ 
 
